ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS
1. **NAME OF THE MEDICINAL PRODUCT**

Descovy 200 mg/10 mg film-coated tablets

2. **QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.

3. **PHARMACEUTICAL FORM**

Film-coated tablet.

Grey, rectangular-shaped, film-coated tablet of dimensions 12.5 mm x 6.4 mm debossed with “GSI” on one side and “210” on the other side of the tablet.

4. **CLINICAL PARTICULARS**

4.1 **Therapeutic indications**

Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see sections 4.2 and 5.1).

4.2 **Posology and method of administration**

Therapy should be initiated by a physician experienced in the management of HIV infection.

**Posology**

*Adults and adolescents aged 12 years and older, weighing at least 35 kg*

Descovy should be administered as shown in Table 1.

<table>
<thead>
<tr>
<th>Dose of Descovy</th>
<th>Third agent in HIV treatment regimen (see section 4.5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Descovy 200/10 mg once daily</td>
<td>Atazanavir with ritonavir or cobicistat Darunavir with ritonavir or cobicistat¹ Lopinavir with ritonavir</td>
</tr>
<tr>
<td>Descovy 200/25 mg once daily</td>
<td>Dolutegravir, efavirenz, maraviroc, nevirapine, rilpivirine, raltegravir</td>
</tr>
</tbody>
</table>

¹ Descovy 200/10 mg in combination with darunavir 800 mg and cobicistat 150 mg, administered as a fixed-dose combination tablet, was studied in treatment-naïve subjects, see section 5.1.

If the patient misses a dose of Descovy within 18 hours of the time it is usually taken, the patient should take Descovy as soon as possible and resume the normal dosing schedule. If a patient misses a dose of Descovy by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
If the patient vomits within 1 hour of taking Descovy another tablet should be taken.

**Elderly**
No dose adjustment of Descovy is required in elderly patients (see sections 5.1 and 5.2).

**Renal impairment**
No dose adjustment of Descovy is required in adults or adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥ 30 mL/min.

Descovy should not be initiated in patients with estimated CrCl < 30 mL/min as there are limited data available regarding the use of Descovy in this population (see sections 5.1 and 5.2).

Descovy should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).

**Hepatic impairment**
No dose adjustment of Descovy is required in patients with hepatic impairment.

**Paediatric population**
The safety and efficacy of Descovy in children younger than 12 years of age, or weighing < 35 kg, have not yet been established. No data are available.

**Method of administration**
Descovy should be taken orally, once daily with or without food (see section 5.2). The film-coated tablet should not be chewed, crushed, or split.

### 4.3 Contraindications
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

### 4.4 Special warnings and precautions for use
While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance with national guidelines.

**Patients co-infected with HIV and hepatitis B or C virus**

Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.

The safety and efficacy of Descovy in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.

Tenofovir alafenamide is active against hepatitis B virus (HBV). Discontinuation of Descovy therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis. Patients co-infected with HIV and HBV who discontinue Descovy should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.

**Liver disease**
The safety and efficacy of Descovy in patients with significant underlying liver disorders have not been established (see sections 4.2 and 5.2).
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.

Weight and metabolic parameters

An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and lifestyle. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.

Mitochondrial dysfunction following exposure in utero

Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia). These events have often been transitory. Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.

Immune Reactivation Syndrome

In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and *Pneumocystis jirovecii* pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.

Autoimmune disorders (such as Graves’ disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment.

Patients with HIV-1 harbouring mutations

Descovy should be avoided in antiretroviral-experienced patients with HIV-1 harbouring the K65R mutation (see section 5.1).

Triple nucleoside therapy

There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. Therefore, the same problems may be seen if Descovy is administered with a third nucleoside analogue.
**Opportunistic infections**

Patients receiving Descovy or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and, therefore, should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.

**Osteonecrosis**

Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.

**Nephrotoxicity**

A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded (see section 5.3).

**Co-administration of other medicinal products**

The co-administration of Descovy is not recommended with certain anticonvulsants (e.g., carbamazepine, oxicarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g., rifampicin, rifabutin, rifapentine), boceprevir, St. John’s wort and HIV protease inhibitors (PIs) other than atazanavir, lopinavir and darunavir (see section 4.5).

Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil.

### 4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults.

Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil.

**Emtricitabine**

*In vitro* and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP-mediated interactions involving emtricitabine with other medicinal products is low. Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine, and/or the co-administered medicinal product. Medicinal products that decrease renal function may increase concentrations of emtricitabine.

**Tenofovir alafenamide**

Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Medicinal products that strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide absorption. Medicinal products that induce P-gp activity (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Descovy and development of resistance. Co-administration of Descovy with other medicinal products that inhibit P-gp and BCRP activity (e.g., cobicistat, ritonavir, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide. Based on data from an *in vitro* study, co-administration of tenofovir alafenamide and xanthine oxidase inhibitors (e.g., febuxostat) is not expected to increase systemic exposure to tenofovir *in vivo*.
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 \textit{in vitro}. It is not an inhibitor or inducer of CYP3A \textit{in vivo}. Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 \textit{in vitro}. The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3.

Other interactions

Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT) 1A1 \textit{in vitro}. It is not known whether tenofovir alafenamide is an inhibitor of other UGT enzymes. Emtricitabine did not inhibit the glucuronidation reaction of a non-specific UGT substrate \textit{in vitro}.

Interactions between the components of Descovy and potential co-administered medicinal products are listed in Table 2 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”). The interactions described are based on studies conducted with Descovy, or the components of Descovy as individual agents and/or in combination, or are potential drug-drug interactions that may occur with Descovy.

Table 2: Interactions between the individual components of Descovy and other medicinal products

<table>
<thead>
<tr>
<th>Medicinal product by therapeutic areas</th>
<th>Effects on medicinal product levels. Mean percent change in AUC, $C_{\text{max}}$, $C_{\text{min}}$</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTI-INFECTIVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Antifungals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Interaction not studied with either of the components of Descovy.</td>
<td>The recommended dose of Descovy is 200/10 mg once daily.</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Co-administration of ketoconazole or itraconazole, which are potent P-gp inhibitors, is expected to increase plasma concentrations of tenofovir alafenamide.</td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>Interaction not studied with either of the components of Descovy.</td>
<td>Dose Descovy according to the concomitant antiretroviral (see section 4.2).</td>
</tr>
<tr>
<td>Isavuconazole</td>
<td>Co-administration of fluconazole or isavuconazole may increase plasma concentrations of tenofovir alafenamide.</td>
<td></td>
</tr>
<tr>
<td><strong>Antimycobacterials</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifabutin</td>
<td>Interaction not studied with either of the components of Descovy.</td>
<td>Co-administration of Descovy and rifabutin rifampicin, or rifapentine is not recommended.</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>Co-administration of rifampicin, rifabutin, and rifapentine, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</td>
<td></td>
</tr>
<tr>
<td>Rifapentine</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anti-hepatitis C virus medicinal products</strong></td>
<td>Interaction not studied with either of the components of Descovy.</td>
<td>Co-administration with boceprevir has the potential to adversely affect the intracellular activation and clinical antiviral efficacy of tenofovir alafenamide, therefore co-administration of Descovy and boceprevir is not recommended.</td>
</tr>
<tr>
<td>Boceprevir</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicinal product by therapeutic areas</td>
<td>Effects on medicinal product levels. Mean percent change in AUC, $\text{C}<em>{\text{max}}, \text{C}</em>{\text{min}}$</td>
<td>Recommendation concerning co-administration with Descovy</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>-------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
</tbody>
</table>
| Ledipasvir (90 mg once daily)/ sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily) | Ledipasvir:  
AUC: ↑ 79%  
$\text{C}_{\text{max}}$: ↑ 65%  
$\text{C}_{\text{min}}$: ↑ 93%  
Sofosbuvir:  
AUC: ↑ 47%  
$\text{C}_{\text{max}}$: ↑ 29%  
Sofosbuvir metabolite GS-331007:  
AUC: ↑ 48%  
$\text{C}_{\text{max}}$: ↔  
$\text{C}_{\text{min}}$: ↑ 66%  
Emtricitabine:  
AUC: ↔  
$\text{C}_{\text{max}}$: ↔  
$\text{C}_{\text{min}}$: ↔  
Tenofovir alafenamide:  
AUC: ↔  
$\text{C}_{\text{max}}$: ↔ | No dose adjustment of ledipasvir or sofosbuvir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |
| Ledipasvir (90 mg once daily)/ sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (25 mg once daily) | Ledipasvir:  
AUC: ↔  
$\text{C}_{\text{max}}$: ↔  
$\text{C}_{\text{min}}$: ↔  
Sofosbuvir:  
AUC: ↔  
$\text{C}_{\text{max}}$: ↔  
Sofosbuvir metabolite GS-331007:  
AUC: ↔  
$\text{C}_{\text{max}}$: ↔  
$\text{C}_{\text{min}}$: ↔  
Emtricitabine:  
AUC: ↔  
$\text{C}_{\text{max}}$: ↔  
$\text{C}_{\text{min}}$: ↔  
Tenofovir alafenamide:  
AUC: ↑ 32%  
$\text{C}_{\text{max}}$: ↔ | No dose adjustment of ledipasvir or sofosbuvir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |
<table>
<thead>
<tr>
<th>Medicinal product by therapeutic areas</th>
<th>Effects on medicinal product levels, Mean percent change in AUC, $C_{\text{max}}, C_{\text{min}}$</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
</table>
| Sofosbuvir (400 mg once daily)/ velpatasvir (100 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily) | Sofosbuvir:  
AUC: ↑ 37%  
$C_{\text{max}}$: ↔  
Sofosbuvir metabolite GS-331007:  
AUC: ↑ 48%  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↑ 58%  
Velpatasvir:  
AUC: ↑ 50%  
$C_{\text{max}}$: ↑ 30%  
$C_{\text{min}}$: ↑ 60%  
Emtricitabine:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  
Tenofovir alafenamide:  
AUC: ↔  
$C_{\text{max}}$: ↓ 20% | No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |
| Sofosbuvir/velpatasvir/ voxilaprevir (400 mg/100 mg/100 mg+100 mg once daily)/ emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily) | Sofosbuvir:  
AUC: ↔  
$C_{\text{max}}$: ↑ 27%  
Sofosbuvir metabolite GS-331007:  
AUC: ↑ 43%  
$C_{\text{max}}$: ↔  
Velpatasvir:  
AUC: ↔  
$C_{\text{max}}$: ↑ 46%  
$C_{\text{min}}$: ↔  
Voxilaprevir:  
AUC: ↑ 171%  
$C_{\text{min}}$: ↑ 350%  
$C_{\text{max}}$: ↑ 92%  
Emtricitabine:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  
Tenofovir alafenamide:  
AUC: ↔  
$C_{\text{max}}$: ↓ 21% | |

8
### Medicinal product by therapeutic areas

<table>
<thead>
<tr>
<th>Medicinal product</th>
<th>Effects on medicinal product levels. Mean percent change in AUC, $C_{\text{max}}, C_{\text{min}}$</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
</table>
| Sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/100 mg+100 mg once daily)²/entecavir (200 mg once daily)/tenofovir alafenamide (25 mg once daily)³ | Sofosbuvir: $AUC: \leftrightarrow$  
$C_{\text{max}}: \leftrightarrow$  
Sofosbuvir metabolite GS-331007: $AUC: \leftrightarrow$  
$C_{\text{min}}: \leftrightarrow$  
Velpatasvir: $AUC: \leftrightarrow$  
$C_{\text{min}}: \leftrightarrow$  
$C_{\text{max}}: \leftrightarrow$  
Voxilaprevir: $AUC: \leftrightarrow$  
$C_{\text{min}}: \leftrightarrow$  
$C_{\text{max}}: \leftrightarrow$  
Entecavir: $AUC: \leftrightarrow$  
$C_{\text{min}}: \leftrightarrow$  
$C_{\text{max}}: \leftrightarrow$  
Tenofovir alafenamide: $AUC: \uparrow 52\%$  
$C_{\text{max}}: \uparrow 32\%$ | No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |

### ANTIRETROVIRALS

#### HIV protease inhibitors

| HIV protease inhibitors | Tenofovir alafenamide: $AUC: \uparrow 75\%$  
$C_{\text{max}}: \uparrow 80\%$  
Atazanavir: $AUC: \leftrightarrow$  
$C_{\text{max}}: \leftrightarrow$  
$C_{\text{min}}: \leftrightarrow$ | The recommended dose of Descovy is 200/10 mg once daily. |
|------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------|
| Atazanavir/ritonavir (300/100 mg once daily), tenofovir alafenamide (10 mg) | Tenofovir alafenamide: $AUC: \uparrow 91\%$  
$C_{\text{max}}: \uparrow 77\%$  
Atazanavir: $AUC: \leftrightarrow$  
$C_{\text{max}}: \leftrightarrow$  
$C_{\text{min}}: \leftrightarrow$ | The recommended dose of Descovy is 200/10 mg once daily. |
| Darunavir/cobicistat (800/150 mg once daily), tenofovir alafenamide (25 mg once daily)⁵ | Tenofovir alafenamide: $AUC: \leftrightarrow$  
$C_{\text{max}}: \leftrightarrow$  
Tenofovir: $AUC: \uparrow 224\%$  
$C_{\text{max}}: \uparrow 216\%$  
$C_{\text{min}}: \uparrow 221\%$  
Darunavir: $AUC: \leftrightarrow$  
$C_{\text{max}}: \leftrightarrow$  
$C_{\text{min}}: \leftrightarrow$ | The recommended dose of Descovy is 200/10 mg once daily. |
<table>
<thead>
<tr>
<th>Medicinal product by therapeutic areas</th>
<th>Effects on medicinal product levels. Mean percent change in AUC, $C_{\text{max}}$, $C_{\text{min}}$&lt;sup&gt;2&lt;/sup&gt;</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
</table>
| Darunavir/ritonavir (800/100 mg once daily), tenofovir alafenamide (10 mg once daily) | Tenofovir alafenamide:  
AUC: ↔  
$C_{\text{max}}$: ↔  
Tenofovir:  
AUC: ↑ 105%  
$C_{\text{max}}$: ↑ 142%  
Darunavir:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  | The recommended dose of Descovy is 200/10 mg once daily. |
| Lopinavir/ritonavir (800/200 mg once daily), tenofovir alafenamide (10 mg once daily) | Tenofovir alafenamide:  
AUC: ↑ 47%  
$C_{\text{max}}$: ↑ 119%  
Lopinavir:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  | The recommended dose of Descovy is 200/10 mg once daily. |
| Tipranavir/ritonavir | Interaction not studied with either of the components of Descovy.  
Tipranavir/ritonavir results in P-gp induction. Tenofovir alafenamide exposure is expected to decrease when tipranavir/ritonavir is used in combination with Descovy. | Co-administration with Descovy is not recommended. |
| Other protease inhibitors | Effect is unknown. | There are no data available to make dosing recommendations for co-administration with other protease inhibitors. |
| **Other HIV antiretrovirals** | | |
| Dolutegravir (50 mg once daily), tenofovir alafenamide (10 mg once daily)<sup>3</sup> | Tenofovir alafenamide:  
AUC: ↔  
$C_{\text{max}}$: ↔  
Dolutegravir:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  | The recommended dose of Descovy is 200/25 mg once daily. |
| Rilpivirine (25 mg once daily), tenofovir alafenamide (25 mg once daily) | Tenofovir alafenamide:  
AUC: ↔  
$C_{\text{max}}$: ↔  
Rilpivirine:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  | The recommended dose of Descovy is 200/25 mg once daily. |
| Efavirenz (600 mg once daily), tenofovir alafenamide (40 mg once daily)<sup>4</sup> | Tenofovir alafenamide:  
AUC: ↓ 14%  
$C_{\text{max}}$: ↓ 22%  | The recommended dose of Descovy is 200/25 mg once daily. |
<table>
<thead>
<tr>
<th>Medicinal product by therapeutic areas</th>
<th>Effects on medicinal product levels. Mean percent change in AUC, $C_{\text{max}}, C_{\text{min}}$</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maravirocu, Nevirapine, Raltegravir</td>
<td>Interaction not studied with either of the components of Descovy. Tenofovir alafenamide exposure is not expected to be affected by maravirocu, nevirapine or raltegravir, nor is it expected to affect the metabolic and excretion pathways relevant to maravirocu, nevirapine or raltegravir.</td>
<td>The recommended dose of Descovy is 200/25 mg once daily.</td>
</tr>
</tbody>
</table>

**ANTICONVULSANTS**

| Oxcarbazepine, Phenobarbital, Phenytoin | Interaction not studied with either of the components of Descovy. Co-administration of oxcarbazepine, phenobarbital, or phenytoin, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. | Co-administration of Descovy and oxcarbazepine, phenobarbital or phenytoin is not recommended. |

| Carbamazepine (titrated from 100 mg to 300 mg twice a day), emtricitabine/tenofovir alafenamide (200 mg/25 mg once daily) | Tenofovir alafenamide: AUC: ↓55% $C_{\text{max}}$: ↓57% Co-administration of carbamazepine, a P-gp inducer, decreases tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. | Co-administration of Descovy and carbamazepine is not recommended. |

**ANTIDEPRESSANTS**

| Sertraline (50 mg once daily), tenofovir alafenamide (10 mg once daily) | Tenofovir alafenamide: AUC: ↔ $C_{\text{max}}$: ↔ Sertraline: AUC: ↑9% $C_{\text{max}}$: ↑14% | No dose adjustment of sertraline is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |

**HERBAL PRODUCTS**

| St. John’s wort (Hypericum perforatum) | Interaction not studied with either of the components of Descovy. Co-administration of St. John’s wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. | Co-administration of Descovy with St. John’s wort is not recommended. |

**IMMUNOSUPPRESSANTS**

| Ciclosporin | Interaction not studied with either of the components of Descovy. Co-administration of ciclosporin, a potent P-gp inhibitor, is expected to increase plasma concentrations of tenofovir alafenamide. | The recommended dose of Descovy is 200/10 mg once daily. |
### Medicinal product by therapeutic areas

<table>
<thead>
<tr>
<th>Therapeutic Areas</th>
<th>Effects on medicinal product levels, mean percent change in AUC, C&lt;sub&gt;max&lt;/sub&gt;, C&lt;sub&gt;min&lt;/sub&gt;</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORAL CONTRACEPTIVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norgestimate (0.180/0.215/0.250 mg once daily), ethinylestradiol (0.025 mg once daily), emtricitabine/tenofovir alafenamide (200/25 mg once daily)&lt;sup&gt;5&lt;/sup&gt;</td>
<td>Norelgestromin: AUC: ↔ C&lt;sub&gt;min&lt;/sub&gt;: ↔ C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td>No dose adjustment of norgestimate/ethinylestradiol is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).</td>
</tr>
<tr>
<td></td>
<td>Norgestrel: AUC: ↔ C&lt;sub&gt;min&lt;/sub&gt;: ↔ C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ethinylestradiol: AUC: ↔ C&lt;sub&gt;min&lt;/sub&gt;: ↔ C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
</tr>
<tr>
<td><strong>SEDATIVES/HYPNOTICS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orally administered midazolam (2.5 mg single dose), tenofovir alafenamide (25 mg once daily)</td>
<td>Midazolam: AUC: ↔ C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td>No dose adjustment of midazolam is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).</td>
</tr>
<tr>
<td>Intravenously administered midazolam (1 mg single dose), tenofovir alafenamide (25 mg once daily)</td>
<td>Midazolam: AUC: ↔ C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
</tr>
</tbody>
</table>

---

1. When doses are provided, they are the doses used in clinical drug-drug interaction studies.
2. When data are available from drug-drug interaction studies.
3. Study conducted with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination tablet.
4. Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.
5. Study conducted with Descovy.
6. Emtricitabine/tenofovir alafenamide was taken with food in this study.
7. Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.

### 4.6 Fertility, pregnancy and lactation

#### Pregnancy

There are no adequate and well-controlled studies of Descovy or its components in pregnant women. There are no or limited data (less than 300 pregnancy outcomes) from the use of tenofovir alafenamide in pregnant women. However, a large amount of data on pregnant women (more than 1,000 exposed outcomes) indicate no malformative nor foetal/neonatal toxicity associated with emtricitabine.

Animal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to fertility parameters, pregnancy, foetal development, parturition or postnatal development. Studies of tenofovir alafenamide in animals have shown no evidence of harmful effects on fertility parameters, pregnancy, or foetal development (see section 5.3).

Descovy should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

#### Breast-feeding

It is not known whether tenofovir alafenamide is excreted in human milk. Emtricitabine is excreted in human milk. In animal studies it has been shown that tenofovir is excreted in milk.

There is insufficient information on the effects of emtricitabine and tenofovir in newborns/infants. Therefore, Descovy should not be used during breast-feeding.
In order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.

**Fertility**

There are no data on fertility from the use of Descovy in humans. In animal studies there were no effects of emtricitabine and tenofovir alafenamide on mating or fertility parameters (see section 5.3).

### 4.7 Effects on ability to drive and use machines

Patients should be informed that dizziness has been reported during treatment with Descovy.

### 4.8 Undesirable effects

**Summary of the safety profile**

Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 3,112 HIV-1 infected patients received medicinal products containing emtricitabine and tenofovir alafenamide. In clinical studies of 866 treatment-naïve adult patients receiving emtricitabine and tenofovir alafenamide with elvitegravir and cobicistat as the fixed-dose combination tablet elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (as fumarate) 10 mg (E/C/F/TAF) through 144 weeks, the most frequently reported adverse reactions were diarrhoea (7%), nausea (11%), and headache (6%).

**Tabulated summary of adverse reactions**

The adverse reactions in Table 3 are listed by system organ class and frequency. Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100).

**Table 3: Tabulated list of adverse reactions**

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Adverse reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td>anaemia*</td>
</tr>
<tr>
<td>Psychiatric disorders</td>
<td>abnormal dreams</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td>headache, dizziness</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>nausea</td>
</tr>
<tr>
<td>Common:</td>
<td>diarrhoea, vomiting, abdominal pain, flatulence</td>
</tr>
<tr>
<td>Uncommon:</td>
<td>dyspepsia</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>rash</td>
</tr>
<tr>
<td>Common:</td>
<td>pruritus, angioedema*</td>
</tr>
<tr>
<td>Uncommon:</td>
<td>arthralgia</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td>fatigue</td>
</tr>
</tbody>
</table>

1 With the exception of angioedema and anaemia (see footnotes 2 and 3), all adverse reactions were identified from clinical studies of F/TAF containing products. The frequencies were derived from Phase 3 E/C/F/TAF clinical studies in 866 treatment-naïve adult patients through 144 weeks of treatment (GS-US-292-0104 and GS-US-292-0111).

2 This adverse reaction was not observed in the clinical studies of F/TAF containing products but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals.

3 This adverse reaction was identified through post-marketing surveillance for emtricitabine but was not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies of emtricitabine. The frequency category of uncommon was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in these clinical studies (n = 1,563).
Description of selected adverse reactions

Immune Reactivation Syndrome
In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves’ disease) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.4).

Osteonecrosis
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see section 4.4).

Changes in lipid laboratory tests
In studies in treatment-naïve patients, increases from baseline were observed in both the tenofovir alafenamide fumarate and tenofovir disoproxil fumarate containing treatment groups for the fasting lipid parameters total cholesterol, direct low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol, and triglycerides at Week 144. The median increase from baseline for those parameters was greater in the E/C/F/TAF group compared with the elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg (E/C/F/TDF) group at Week 144 (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides). The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 144 was 0.2 (-0.3, 0.7) in the E/C/F/TAF group and 0.1 (-0.4, 0.6) in the E/C/F/TDF group (p = 0.006 for the difference between treatment groups).

In a study of virologically suppressed patients switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent (Study GS-US-311-1089), increases from baseline were observed in the fasting lipid parameters total cholesterol, direct LDL cholesterol and triglycerides in the Descovy arm compared with little change in the emtricitabine/tenofovir disoproxil fumarate arm (p ≤ 0.009 for the difference between groups in changes from baseline). There was little change from baseline in median fasting values for HDL cholesterol and glucose, or in the fasting total cholesterol to HDL cholesterol ratio in either treatment arm at Week 96. None of the changes was considered clinically relevant.

In a study of virologically suppressed adult patients switching from abacavir/lamivudine to Descovy while maintaining the third antiretroviral agent (Study GS-US-311-1717), there were minimal changes in lipid parameters.

Metabolic parameters
Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).

Paediatric population
The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in an open-label clinical study (GS-US-292-0106) in which HIV-1 infected, treatment-naïve paediatric patients aged 12 to < 18 years received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet. The safety profile of emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat in 50 adolescent patients was similar to that in adults (see section 5.1).

Other special populations

Patients with renal impairment
The safety of emtricitabine and tenofovir alafenamide was evaluated through 144 weeks in an open-label clinical study (GS-US-292-0112) in which 248 HIV-1 infected patients who were either treatment-naïve (n = 6) or virologically suppressed (n = 242) with mild to moderate renal impairment
(estimated glomerular filtration rate by Cockcroft-Gault method \[eGFR_{CG}\]: 30-69 mL/min) received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet. The safety profile in patients with mild to moderate renal impairment was similar to that in patients with normal renal function (see section 5.1).

**Patients co-infected with HIV and HBV**

The safety of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide \[E/C/F/TAF\]) was evaluated in 72 HIV/HBV co-infected patients receiving treatment for HIV in an open-label clinical study (GS-US-292-1249), through Week 48, in which patients were switched from another antiretroviral regimen (which included tenofovir disoproxil fumarate \[TDF\] in 69 of 72 patients) to E/C/F/TAF. Based on these limited data, the safety profile of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet, in patients with HIV/HBV co-infection, was similar to that in patients with HIV-1 monoinfection (see section 4.4).

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8). Treatment of overdose with Descovy consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.

Emtricitabine can be removed by haemodialysis, which removes approximately 30% of the emtricitabine dose over a 3 hour dialysis period starting within 1.5 hours of emtricitabine dosing. Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%. It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations. ATC code: J05AR17.

**Mechanism of action**

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2'-deoxycytidine. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine triphosphate. Emtricitabine triphosphate inhibits HIV replication through incorporation into viral deoxyribonucleic acid (DNA) by the HIV reverse transcriptase (RT), which results in DNA chain-termination. Emtricitabine has activity against HIV-1, HIV-2, and HBV.

Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue). Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in concentrating tenofovir in peripheral blood mononuclear cells (PBMCs) or HIV target cells including lymphocytes and macrophages. Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits
HIV replication through incorporation into viral DNA by the HIV RT, which results in DNA chain-termination.

Tenofovir has activity against HIV-1, HIV-2, and HBV.

Antiviral activity in vitro

Emtricitabine and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture. No antagonism was observed with emtricitabine or tenofovir alafenamide when combined with other antiretroviral agents.

The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI CCR5 cell line, and PBMCs. The 50% effective concentration (EC₅₀) values for emtricitabine were in the range of 0.0013 to 0.64 μM. Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC₅₀ values ranged from 0.007 to 0.075 μM) and showed strain specific activity against HIV-2 (EC₅₀ values ranged from 0.007 to 1.5 μM).

The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4+ T lymphocytes. The EC₅₀ values for tenofovir alafenamide were in the range of 2.0 to 14.7 nM. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, and O), including subtypes A, B, C, D, E, F, and G (EC₅₀ values ranged from 0.10 to 12.0 nM) and showed strain specific activity against HIV-2 (EC₅₀ values ranged from 0.91 to 2.63 nM).

Resistance

In vitro

Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV-1 RT.

HIV-1 isolates with reduced susceptibility to tenofovir alafenamide express a K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed.

In treatment-naïve patients

In a pooled analysis of antiretroviral-naïve patients receiving emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet in Phase 3 studies GS-US-292-0104 and GS-US-292-0111, genotyping was performed on plasma HIV-1 isolates from all patients with HIV-1 RNA ≥ 400 copies/mL at confirmed virological failure, at Week 144, or at the time of early study drug discontinuation. Through Week 144, the development of one or more primary emtricitabine, tenofovir alafenamide, or elvitegravir resistance-associated mutations was observed in HIV-1 isolates from 12 of 22 patients with evaluable genotypic data from paired baseline and E/C/F/TAF treatment-failure isolates (12 of 866 patients [1.4%]) compared with 12 of 20 treatment-failure isolates from patients with evaluable genotypic data in the E/C/F/TDF group (12 of 867 patients [1.4%]). In the E/C/F/TAF group, the mutations that emerged were M184V/I (n = 11) and K65R/N (n = 2) in RT and T667A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase. Of the HIV-1 isolates from 12 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 9), K65R/N (n = 4), and L210W (n = 1) in RT and E92Q/V (n = 4) and Q148R (n = 2), and N155H/S (n = 3) in integrase. Most HIV-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir in integrase also developed resistance mutations to emtricitabine in RT.

In patients co-infected with HIV and HBV

In a clinical study of HIV virologically suppressed patients co-infected with chronic hepatitis B, who received emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), for 48 weeks (GS-US-292-1249, n = 72), 2 patients qualified for resistance analysis. In these 2 patients, no amino acid substitutions associated with resistance to any of the components of E/C/F/TAF were identified in HIV-1 or HBV.
Cross-resistance in HIV-1 infected, treatment-naïve or virologically suppressed patients

Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.

The K65R and K70E mutations result in reduced susceptibility to abacavir, didanosine, lamivudine, emtricitabine, and tenofovir, but retain sensitivity to zidovudine.

Multinucleoside-resistant HIV-1 with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed reduced susceptibility to tenofovir alafenamide.

Clinical data

There are no efficacy and safety studies conducted in treatment-naïve patients with Descovy.

Clinical efficacy of Descovy was established from studies conducted with emtricitabine and tenofovir alafenamide when given with elvitegravir and cobicistat as the fixed-dose combination tablet E/C/F/TAF.

HIV-1 infected, treatment-naïve patients

In studies GS-US-292-0104 and GS-US-292-0111, patients were randomised in a 1:1 ratio to receive either emtricitabine 200 mg and tenofovir alafenamide 10 mg (n = 866) once daily or emtricitabine 200 mg + tenofovir disoproxil (as fumarate) 245 mg (n = 867) once daily, both given with elvitegravir 150 mg + cobicistat 150 mg as a fixed-dose combination tablet. The mean age was 36 years (range: 18-76), 85% were male, 57% were White, 25% were Black, and 10% were Asian. Nineteen percent of patients were identified as Hispanic/Latino. The mean baseline plasma HIV-1 RNA was 4.5 log_{10} copies/mL (range: 1.3-7.0) and 23% had baseline viral loads > 100,000 copies/mL. The mean baseline CD4+ cell count was 427 cells/mm³ (range: 0-1,360) and 13% had a CD4+ cell count < 200 cells/mm³.

E/C/F/TAF demonstrated statistical superiority in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF at Week 144. The difference in percentage was 4.2% (95% CI: 0.6% to 7.8%). Pooled treatment outcomes at 48 and 144 weeks are shown in Table 4.

Table 4: Pooled virological outcomes of Studies GS-US-292-0104 and GS-US-292-0111 at Weeks 48 and 144a,b

<table>
<thead>
<tr>
<th>HIV-1 RNA &lt; 50 copies/mL</th>
<th>Week 48</th>
<th>Week 144</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>E/C/F/TAF</td>
<td>E/C/F/TDF</td>
</tr>
<tr>
<td>(n = 866)</td>
<td>(n = 867)</td>
<td></td>
</tr>
<tr>
<td>Treatment difference</td>
<td>2.0% (95% CI: -0.7% to 4.7%)</td>
<td>4.2% (95% CI: 0.6% to 7.8%)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HIV-1 RNA ≥ 50 copies/mL</th>
<th>Week 48</th>
<th>Week 144</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>E/C/F/TAF</td>
<td>E/C/F/TDF</td>
</tr>
<tr>
<td>(n = 866)</td>
<td>(n = 867)</td>
<td></td>
</tr>
<tr>
<td>Discontinued study drug due to AE or death</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>Missing data during window but on study drug</td>
<td>1%</td>
<td>&lt; 1%</td>
</tr>
</tbody>
</table>

Proportion (%) of patients with HIV-1 RNA < 50 copies/mL by subgroup
<table>
<thead>
<tr>
<th></th>
<th>Week 48</th>
<th>Week 144</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>E/C/F/TAF</td>
<td>E/C/F/TDF</td>
</tr>
<tr>
<td></td>
<td>(n = 866)</td>
<td>(n = 867)</td>
</tr>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50 years</td>
<td>716/777 (92%)</td>
<td>680/753 (90%)</td>
</tr>
<tr>
<td>≥ 50 years</td>
<td>84/89 (94%)</td>
<td>104/114 (91%)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>674/733 (92%)</td>
<td>673/740 (91%)</td>
</tr>
<tr>
<td>Female</td>
<td>126/133 (95%)</td>
<td>111/127 (87%)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>197/223 (88%)</td>
<td>177/213 (83%)</td>
</tr>
<tr>
<td>Non-black</td>
<td>603/643 (94%)</td>
<td>607/654 (93%)</td>
</tr>
<tr>
<td>Baseline viral load</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 100,000 copies/mL</td>
<td>629/670 (94%)</td>
<td>610/672 (91%)</td>
</tr>
<tr>
<td>&gt; 100,000 copies/mL</td>
<td>171/196 (87%)</td>
<td>174/195 (89%)</td>
</tr>
<tr>
<td>Baseline CD4+ cell count</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 200 cells/mm³</td>
<td>96/112 (86%)</td>
<td>104/117 (89%)</td>
</tr>
<tr>
<td>≥ 200 cells/mm³</td>
<td>703/753 (93%)</td>
<td>680/750 (91%)</td>
</tr>
<tr>
<td>HIV-1 RNA &lt; 20 copies/mL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment difference</td>
<td>84.4%</td>
<td>84.0%</td>
</tr>
<tr>
<td></td>
<td>0.4% (95% CI: -3.0% to 3.8%)</td>
<td>5.4% (95% CI: 1.5% to 9.2%)</td>
</tr>
</tbody>
</table>

E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
E/C/F/TDF = elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate

a Week 48 window was between Day 294 and 377 (inclusive); Week 144 window was between Day 966 and 1049 (inclusive).
b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US).
c Included patients who had ≥ 50 copies/mL in the Week 48 or 144 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
d Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
e Includes patients who discontinued for reasons other than an AE, death or lack of efficacy; e.g., withdrew consent, loss to follow-up, etc.

The mean increase from baseline in CD4+ cell count was 230 cells/mm³ in patients receiving E/C/F/TAF and 211 cells/mm³ in patients receiving E/C/F/TDF (p = 0.024) at Week 48, and 326 cells/mm³ in E/C/F/TAF-treated patients and 305 cells/mm³ in E/C/F/TDF-treated patients (p = 0.06) at Week 144.

Clinical efficacy of Descovy in treatment-naïve patients was also established from a study conducted with emtricitabine and tenofovir alafenamide (10 mg) when given with darunavir (800 mg) and cobicistat as a fixed-dose combination tablet (D/C/F/TAF). In Study GS-US-299-0102, patients were randomised in a 2:1 ratio to receive either fixed-dose combination D/C/F/TAF once daily (n = 103) or darunavir and cobicistat and emtricitabine/tenofovir disoproxil fumarate once daily (n = 50). The proportions of patients with plasma HIV-1 RNA < 50 copies/mL and < 20 copies/mL are shown in Table 5.
Table 5: Virological outcomes of Study GS-US-299-0102 at Week 24 and 48a

<table>
<thead>
<tr>
<th></th>
<th>Week 24</th>
<th></th>
<th>Week 48</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D/C/F/TAF</td>
<td>Darunavir,</td>
<td>D/C/F/TAF</td>
<td>Darunavir,</td>
</tr>
<tr>
<td></td>
<td>(n = 103)</td>
<td>cobicistat and</td>
<td>(n = 103)</td>
<td>cobicistat and</td>
</tr>
<tr>
<td></td>
<td></td>
<td>emtricitabine/tenofovir</td>
<td></td>
<td>emtricitabine/tenofovir</td>
</tr>
<tr>
<td>HIV-1 RNA &lt; 50 copies/mL</td>
<td>75%</td>
<td>74%</td>
<td>77%</td>
<td>84%</td>
</tr>
<tr>
<td>Treatment difference</td>
<td>3.3% (95% CI: -11.4% to 18.1%)</td>
<td>-6.2% (95% CI: -19.9% to 7.4%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HIV-1 RNA ≥ 50 copies/mLb</td>
<td>20%</td>
<td>24%</td>
<td>16%</td>
<td>12%</td>
</tr>
<tr>
<td>No virologic data at Week 48 window</td>
<td>5%</td>
<td>2%</td>
<td>8%</td>
<td>4%</td>
</tr>
<tr>
<td>Discontinued study drug due to AE or deathc</td>
<td>1%</td>
<td>0</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>Discontinued study drug due to other reasons and last available HIV-1 RNA &lt; 50 copies/mLd</td>
<td>4%</td>
<td>2%</td>
<td>7%</td>
<td>2%</td>
</tr>
<tr>
<td>Missing data during window but on study drug</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>HIV-1 RNA &lt; 20 copies/mL</td>
<td>55%</td>
<td>62%</td>
<td>63%</td>
<td>76%</td>
</tr>
<tr>
<td>Treatment difference</td>
<td>-3.5% (95% CI: -19.8% to 12.7%)</td>
<td>-10.7% (95% CI: -26.3% to 4.8%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D/C/F/TAF = darunavir/cobicistat/emtricitabine/tenofovir alafenamide

a Week 48 window was between Day 294 and 377 (inclusive).
b Included patients who had ≥ 50 copies/mL in the Week 48 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
c Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
d Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.

HIV-1 infected virologically suppressed patients

In Study GS-US-311-1089, the efficacy and safety of switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults (n = 663). Patients must have been stably suppressed (HIV-1 RNA < 50 copies/mL) on their baseline regimen for at least 6 months and had HIV-1 with no resistance mutations to emtricitabine or tenofovir alafenamide prior to study entry. Patients were randomised in a 1:1 ratio to either switch to Descovy (n = 333), or stay on their baseline emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330). Patients were stratified by the class of the third agent in their prior treatment regimen. At baseline, 46% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with a boosted PI and 54% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with an unboosted third agent.

Treatment outcomes of Study GS-US-311-1089 through 48 and 96 weeks are presented in Table 6.
Table 6: Virological outcomes of Study GS-US-311-1089 at Weeks 48\(^a\) and 96\(^b\)

<table>
<thead>
<tr>
<th></th>
<th>Week 48</th>
<th>Week 96</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Descovy containing regimen (n = 333)</td>
<td>Emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330)</td>
</tr>
<tr>
<td>HIV-1 RNA &lt; 50 copies/mL</td>
<td>94%</td>
<td>93%</td>
</tr>
<tr>
<td>Treatment difference</td>
<td>1.3% (95% CI: -2.5% to 5.1%)</td>
<td>-0.5% (95% CI: -5.3% to 4.4%)</td>
</tr>
<tr>
<td>HIV-1 RNA ≥ 50 copies/mL</td>
<td>&lt; 1%</td>
<td>2%</td>
</tr>
<tr>
<td>No virologic data at Week 48 or 96 window</td>
<td>5%</td>
<td>5%</td>
</tr>
<tr>
<td>Discontinued study drug due to AE or death(^d)</td>
<td>2%</td>
<td>1%</td>
</tr>
<tr>
<td>Discontinued study drug due to other reasons and last available HIV-1 RNA &lt; 50 copies/mL</td>
<td>3%</td>
<td>5%</td>
</tr>
<tr>
<td>Missing data during window but on study drug</td>
<td>&lt; 1%</td>
<td>0</td>
</tr>
<tr>
<td>Proportion (%) of patients with HIV-1 RNA &lt; 50 copies/mL by prior treatment regimen</td>
<td>Boosted PIs 142/155 (92%)</td>
<td>140/151 (93%)</td>
</tr>
<tr>
<td>Other third agents</td>
<td>172/178 (97%)</td>
<td>167/179 (93%)</td>
</tr>
</tbody>
</table>

PI = protease inhibitor

- Week 48 window was between Day 294 and 377 (inclusive).
- Week 96 window was between Day 630 and 713 (inclusive).
- Included patients who had ≥ 50 copies/mL in the Week 48 or Week 96 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
- Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
- Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.

In Study GS-US-311-1717, patients who were virologically suppressed (HIV-1 RNA <50 copies/mL) on their abacavir/lamivudine containing regimen for at least 6 months were randomised in a 1:1 ratio to either switch to Descovy (N=280) while maintaining their third agent at baseline or stay on their baseline abacavir/lamivudine -containing regimen (N=276).

Patients were stratified by the class of the third agent in their prior treatment regimen. At baseline, 30% of patients were receiving abacavir/lamivudine in combination with a boosted protease inhibitor and 70% of patients were receiving abacavir/lamivudine in combination with an unboosted third agent. Virologic success rates at Week 48 were: Descovy Containing Regimen: 89.7% (227 of 253 subjects); Abacavir/lamivudine Containing Regimen: 92.7% (230 of 248 subjects). At Week 48, switching to a
Descovy-containing regimen was non-inferior to staying on a baseline abacavir/lamivudine-containing regimen in maintaining HIV-1 RNA < 50 copies/mL.

**HIV-1 infected patients with mild to moderate renal impairment**

In Study GS-US-292-0112, the efficacy and safety of emtricitabine and tenofovir alafenamide were evaluated in an open-label clinical study in which 242 HIV-1 infected patients with mild to moderate renal impairment (eGFR\textsubscript{Ccr}: 30-69 mL/min) were switched to emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet. Patients were virologically suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months before switching.

The mean age was 58 years (range: 24-82), with 63 patients (26%) who were ≥ 65 years of age. Seventy-nine percent were male, 63% were White, 18% were Black, and 14% were Asian. Thirteen percent of patients were identified as Hispanic/Latino. At baseline, median eGFR was 56 mL/min, and 33% of patients had an eGFR from 30 to 49 mL/min. The mean baseline CD4+ cell count was 664 cells/mm\(^3\) (range: 126-1,813).

At Week 144, 83.1% (197/237 patients) maintained HIV-1 RNA < 50 copies/mL after switching to emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet.

**Patients co-infected with HIV and HBV**

In open-label Study GS-US-292-1249, the efficacy and safety of emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), were evaluated in adult patients co-infected with HIV-1 and chronic hepatitis B. Sixty-nine of the 72 patients were on prior TDF-containing antiretroviral therapy. At the start of treatment with E/C/F/TAF, the 72 patients had been HIV-suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months with or without suppression of HBV DNA and had compensated liver function. The mean age was 50 years (range 28-67), 92% of patients were male, 69% were White, 18% were Black, and 10% were Asian. The mean baseline CD4+ cell count was 636 cells/mm\(^3\) (range 263-1,498). Eighty-six percent of patients (62/72) were HBV suppressed (HBV DNA < 29 IU/mL) and 42% (30/72) were HBeAg positive at baseline.

Of the patients who were HBeAg positive at baseline, 1/30 (3.3%) achieved seroconversion to anti-HBe at Week 48. Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti-HBs Week 48.

At Week 48, 92% of patients (66/72) maintained HIV-1 RNA < 50 copies/mL after switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet. The mean change from baseline in CD4+ cell count at Week 48 was -2 cells/mm\(^3\). Ninety-two percent (66/72 patients) had HBV DNA < 29 IU/mL using missing = failure analysis at Week 48. Of the 62 patients who were HBV suppressed at baseline, 59 remained suppressed and 3 had missing data. Of the 10 patients who were not HBV suppressed at baseline (HBV DNA ≥ 29 IU/mL), 7 became suppressed, 2 remained detectable, and 1 had missing data.

There are limited clinical data on the use of E/C/F/TAF in HIV/HBV co-infected patients who are treatment-naïve.

**Changes in measures of bone mineral density**

In studies in treatment-naïve patients, emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet was associated with smaller reductions in bone mineral density (BMD) compared to E/C/F/TDF through 144 weeks of treatment as measured by dual energy X ray absorptiometry (DXA) analysis of hip (mean change: −0.8% vs −3.4%, p < 0.001) and lumbar spine (mean change: −0.9% vs −3.0%, p < 0.001). In a separate study, emtricitabine and tenofovir alafenamide given with darunavir and cobicistat as a fixed-dose combination tablet was also associated with smaller reductions in BMD (as measured by hip and lumbar spine DXA analysis) through 48 weeks of treatment compared to darunavir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.
In a study in virologically suppressed adult patients, improvements in BMD were noted through 96 weeks after switching to Descovy from a TDF containing regimen compared to minimal changes with maintaining the TDF containing regimen as measured by DXA analysis of hip (mean change from baseline of 1.9% vs -0.3%, p < 0.001) and lumbar spine (mean change from baseline of 2.2% vs -0.2%, p < 0.001).

In a study in virologically suppressed adult patients, BMD did not change significantly through 48 weeks after switching to Descovy from an abacavir/lamivudine containing regimen compared to maintaining the abacavir/lamivudine containing regimen as measured by DXA analysis of hip (mean change from baseline of 0.3% vs 0.2%, p = 0.55) and lumbar spine (mean change from baseline of 0.1% vs < 0.1%, p = 0.78).

**Changes in measures of renal function**

In studies in treatment-naïve patients, emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet through 144 weeks was associated with a lower impact on renal safety parameters (as measured after 144 weeks treatment by eGFR_{CG} and urine protein to creatinine ratio and after 96 weeks treatment by urine albumin to creatinine ratio) compared to E/C/F/TDF. Through 144 weeks of treatment, no subject discontinued E/C/F/TAF due to a treatment-emergent renal adverse event compared with 12 subjects who discontinued E/C/F/TDF (p < 0.001).

In a separate study in treatment-naïve patients, emtricitabine and tenofovir alafenamide given with darunavir and cobicistat as a fixed-dose combination tablet was associated with a lower impact on renal safety parameters through 48 weeks of treatment compared to darunavir and cobicistat given with emtricitabine/tenofovir disoproxil fumarate (see also section 4.4).

In a study in virologically suppressed adult patients measures of tubular proteinuria were similar in patients switching to a regimen containing Descovy compared to patients who stayed on an abacavir/lamivudine containing regimen at baseline. At Week 48, the median percentage change in urine retinol binding protein to creatinine ratio was 4% in the Descovy group and 16% in those remaining on an abacavir/lamivudine containing regimen; and in urine beta-2 microglobulin to creatinine ratio it was 4% vs. 5%.

**Paediatric population**

In Study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of emtricitabine and tenofovir alafenamide were evaluated in an open-label study in which 50 HIV-1 infected, treatment-naïve adolescents received emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet. Patients had a mean age of 15 years (range: 12-17), and 56% were female, 12% were Asian, and 88% were Black. At baseline, median plasma HIV-1 RNA was 4.7 log_{10} copies/mL, median CD4+ cell count was 456 cells/mm^{3} (range: 95-1,110), and median CD4+ % was 23% (range: 7-45%). Overall, 22% had baseline plasma HIV-1 RNA > 100,000 copies/mL. At 48 weeks, 92% (46/50) achieved HIV-1 RNA < 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults. The mean increase from baseline in CD4+ cell count at Week 48 was 224 cells/mm^{3}. No emergent resistance to E/C/F/TAF was detected through Week 48.

The European Medicines Agency has deferred the obligation to submit the results of studies with Descovy in one or more subsets of the paediatric population in the treatment of HIV-1 infection (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties

Absorption

Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the (mean ± SD) steady state plasma emtricitabine peak concentrations ($C_{\text{max}}$) were $1.8 \pm 0.7 \mu g/mL$ and the area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was $10.0 \pm 3.1 \mu g\cdot h/mL$. The mean steady state plasma trough concentration at 24 hours post-dose was equal to or greater than the mean in vitro IC90 value for anti-HIV-1 activity.

Emtricitabine systemic exposure was unaffected when emtricitabine was administered with food. Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg). The mean $C_{\text{max}}$ and $\text{AUC}_{\text{last}}$, (mean ± SD) under fed conditions following a single 25 mg dose of tenofovir alafenamide administered in Descovy were $0.21 \pm 0.13 \mu g/mL$ and $0.25 \pm 0.11 \mu g\cdot h/mL$, respectively. The mean $C_{\text{max}}$ and $\text{AUC}_{\text{last}}$ following a single 10 mg dose of tenofovir alafenamide administered in E/C/F/TAF were $0.21 \pm 0.10 \mu g/mL$ and $0.25 \pm 0.08 \mu g\cdot h/mL$, respectively.

Relative to fasting conditions, the administration of tenofovir alafenamide with a high fat meal (~800 kcal, 50% fat) resulted in a decrease in tenofovir alafenamide $C_{\text{max}}$ (15-37%) and an increase in $\text{AUC}_{\text{last}}$ (17-77%).

Distribution

*In vitro* binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 μg/mL. At peak plasma concentration, the mean plasma to blood drug concentration ratio was ~1.0 and the mean semen to plasma drug concentration ratio was ~4.0.

*In vitro* binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 μg/mL. *Ex vivo* binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%.

Biotransformation

*In vitro* studies indicate that emtricitabine is not an inhibitor of human CYP enzymes. Following administration of $[^{14}\text{C}]-\text{emtricitabine}$, complete recovery of the emtricitabine dose was achieved in urine (~86%) and faeces (~14%). Thirteen percent of the dose was recovered in the urine as three putative metabolites. The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3’-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2’-O-glucuronide (~4% of dose). No other metabolites were identifiable.

Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for > 80% of an oral dose. *In vitro* studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by cathepsin A in PBMCs (including lymphocytes and other HIV target cells) and macrophages; and by carboxylesterase-1 in hepatocytes. *In vivo*, tenofovir alafenamide is hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite tenofovir diphosphate. In human clinical studies, a 10 mg oral dose of tenofovir alafenamide (given with emtricitabine and elvitegravir and cobicistat) resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) (given with emtricitabine and elvitegravir and cobicistat).
In vitro, tenofovir alafenamide is not metabolised by CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. Tenofovir alafenamide is minimally metabolised by CYP3A4. Upon co-administration with the moderate CYP3A inducer probe efavirenz, tenofovir alafenamide exposure was not significantly affected. Following administration of tenofovir alafenamide, plasma $^{14}$C-radioactivity showed a time-dependent profile with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.

Elimination

Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). Thirteen percent of the emtricitabine dose was recovered in urine as three metabolites. The systemic clearance of emtricitabine averaged 307 mL/min. Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours.

Renal excretion of intact tenofovir alafenamide is a minor pathway with < 1% of the dose eliminated in urine. Tenofovir alafenamide is mainly eliminated following metabolism to tenofovir. Tenofovir alafenamide and tenofovir have a median plasma half-life of 0.51 and 32.37 hours, respectively. Tenofovir is renally eliminated by both glomerular filtration and active tubular secretion.

Pharmacokinetics in special populations

Age, gender, and ethnicity

No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, or tenofovir alafenamide.

Paediatric population

Exposures of emtricitabine and tenofovir alafenamide (given with elvitegravir and cobicistat) achieved in 24 paediatric patients aged 12 to < 18 years who received emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat in Study GS-US-292-0106 were similar to exposures achieved in treatment-naïve adults (Table 7).

Table 7: Pharmacokinetics of emtricitabine and tenofovir alafenamide in antiretroviral-naïve adolescents and adults

<table>
<thead>
<tr>
<th></th>
<th>Adolescents</th>
<th>Adults</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FTC$^a$</td>
<td>TAF$^b$</td>
<td>TFV$^b$</td>
<td>FTC$^a$</td>
</tr>
<tr>
<td>AUC$^{\text{tau}}$ (ng·h/mL)</td>
<td>14,424.4 (23.9)</td>
<td>242.8 (57.8)</td>
<td>275.8 (18.4)</td>
<td>11,714.1 (16.6)</td>
</tr>
<tr>
<td>$C_{\text{max}}$ (ng/mL)</td>
<td>2,265.0 (22.5)</td>
<td>121.7 (46.2)</td>
<td>14.6 (20.0)</td>
<td>2,056.3 (20.2)</td>
</tr>
<tr>
<td>$C_{\text{tau}}$ (ng/mL)</td>
<td>102.4 (38.9)$^b$</td>
<td>N/A</td>
<td>10.0 (19.6)</td>
<td>95.2 (46.7)</td>
</tr>
</tbody>
</table>

E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate
FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir
N/A = not applicable

Data are presented as mean (%CV).

a n = 24 adolescents (GS-US-292-0106); n = 19 adults (GS-US-292-0102)

b n = 23 adolescents (GS-US-292-0106, population PK analysis)

c n = 539 (TAF) or 841 (TFV) adults (GS-US-292-0111 and GS-US-292-0104, population PK analysis)

Renal impairment

No clinically relevant differences in tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and patients with severe renal impairment (estimated CrCl > 15 but < 30 mL/min) in studies of tenofovir alafenamide. There are no pharmacokinetic data on tenofovir alafenamide in patients with estimated CrCl < 15 mL/min. Mean systemic emtricitabine exposure was higher in patients with severe renal impairment (CrCl < 30 mL/min) (33.7 μg·h/mL) than in subjects with normal renal function (11.8 μg·h/mL).
**Hepatic impairment**

The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.

Clinically relevant changes in the pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were not observed in patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, total plasma concentrations of tenofovir alafenamide and tenofovir are lower than those seen in subjects with normal hepatic function. When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.

**Hepatitis B and/or hepatitis C virus co-infection**

The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co-infected with HBV and/or HCV.

5.3 **Preclinical safety data**

Non-clinical data on emtricitabine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Emtricitabine has demonstrated low carcinogenic potential in mice and rats.

Non-clinical studies of tenofovir alafenamide in rats and dogs revealed bone and kidney as the primary target organs of toxicity. Bone toxicity was observed as reduced BMD in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of Descovy. A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17 times greater, respectively, than those expected after administration of Descovy.

Tenofovir alafenamide was not mutagenic or clastogenic in conventional genotoxicity assays.

Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil fumarate, carcinogenicity studies and a rat peri-postnatal study were conducted only with tenofovir disoproxil fumarate. No special hazard for humans was revealed in conventional studies of carcinogenic potential and toxicity to reproduction and development. Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses.

6. **PHARMACEUTICAL PARTICULARS**

6.1 **List of excipients**

**Tablet core**

- Microcrystalline cellulose
- Croscarmellose sodium
- Magnesium stearate
Film-coating

Polyvinyl alcohol
Titanium dioxide
Macrogol 3350
Talc
Iron oxide black (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Store in the original package in order to protect from moisture. Keep the bottle tightly closed.

6.5 Nature and contents of container

High density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined with an induction activated aluminium foil liner containing 30 film-coated tablets. Each bottle contains silica gel desiccant and polyester coil.

The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Gilead Sciences Ireland UC
Carrigtowhill
County Cork, T45 DP77
Ireland

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1099/001
EU/1/16/1099/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 April 2016
10. DATE OF REVISION OF THE TEXT

{MM/YYYY}

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT
Descovy 200 mg/25 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.

3. PHARMACEUTICAL FORM
Film-coated tablet.
Blue, rectangular-shaped, film-coated tablet of dimensions 12.5 mm x 6.4 mm debossed with “GSI” on one side and “225” on the other side of the tablet.

4. CLINICAL PARTICULARS
4.1 Therapeutic indications
Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1) (see sections 4.2 and 5.1).

4.2 Posology and method of administration
Therapy should be initiated by a physician experienced in the management of HIV infection.

Posology

Adults and adolescents aged 12 years and older, weighing at least 35 kg
Descovy should be administered as shown in Table 1.

Table 1: Dose of Descovy according to third agent in the HIV treatment regimen

<table>
<thead>
<tr>
<th>Dose of Descovy</th>
<th>Third agent in HIV treatment regimen (see section 4.5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Descovy 200/10 mg once daily</td>
<td>Atazanavir with ritonavir or cobicistat</td>
</tr>
<tr>
<td></td>
<td>Darunavir with ritonavir or cobicistat</td>
</tr>
<tr>
<td></td>
<td>Lopinavir with ritonavir</td>
</tr>
<tr>
<td>Descovy 200/25 mg once daily</td>
<td>Dolutegravir, efavirenz, maraviroc, nevirapine, rilpivirine, raltegravir</td>
</tr>
</tbody>
</table>

1 Descovy 200/10 mg in combination with darunavir 800 mg and cobicistat 150 mg, administered as a fixed-dose combination tablet, was studied in treatment-naive subjects, see section 5.1.

If the patient misses a dose of Descovy within 18 hours of the time it is usually taken, the patient should take Descovy as soon as possible and resume the normal dosing schedule. If a patient misses a dose of Descovy by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.
If the patient vomits within 1 hour of taking Descovy another tablet should be taken.

**Elderly**
No dose adjustment of Descovy is required in elderly patients (see sections 5.1 and 5.2).

**Renal impairment**
No dose adjustment of Descovy is required in adults or adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥ 30 mL/min.

Descovy should not be initiated in patients with estimated CrCl < 30 mL/min as there are limited data available regarding the use of Descovy in this population (see sections 5.1 and 5.2).

Descovy should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see sections 5.1 and 5.2).

**Hepatic impairment**
No dose adjustment of Descovy is required in patients with hepatic impairment.

**Paediatric population**
The safety and efficacy of Descovy in children younger than 12 years of age, or weighing < 35 kg, have not yet been established. No data are available.

**Method of administration**
Descovy should be taken orally, once daily with or without food (see section 5.2). The film-coated tablet should not be chewed, crushed, or split.

### 4.3 Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.

### 4.4 Special warnings and precautions for use

While effective viral suppression with antiretroviral therapy has been proven to substantially reduce the risk of sexual transmission, a residual risk cannot be excluded. Precautions to prevent transmission should be taken in accordance with national guidelines.

**Patients co-infected with HIV and hepatitis B or C virus**

Patients with chronic hepatitis B or C treated with antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse reactions.

The safety and efficacy of Descovy in patients co-infected with HIV-1 and hepatitis C virus (HCV) have not been established.

Tenofovir alafenamide is active against hepatitis B virus (HBV). Discontinuation of Descovy therapy in patients co-infected with HIV and HBV may be associated with severe acute exacerbations of hepatitis. Patients co-infected with HIV and HBV who discontinue Descovy should be closely monitored with both clinical and laboratory follow-up for at least several months after stopping treatment.

**Liver disease**

The safety and efficacy of Descovy in patients with significant underlying liver disorders have not been established (see sections 4.2 and 5.2).
Patients with pre-existing liver dysfunction, including chronic active hepatitis, have an increased frequency of liver function abnormalities during combination antiretroviral therapy (CART) and should be monitored according to standard practice. If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment must be considered.

Weight and metabolic parameters

An increase in weight and in levels of blood lipids and glucose may occur during antiretroviral therapy. Such changes may in part be linked to disease control and lifestyle. For lipids, there is in some cases evidence for a treatment effect, while for weight gain there is no strong evidence relating this to any particular treatment. For monitoring of blood lipids and glucose reference is made to established HIV treatment guidelines. Lipid disorders should be managed as clinically appropriate.

Mitochondrial dysfunction following exposure in utero

Nucleos(t)ide analogues may impact mitochondrial function to a variable degree, which is most pronounced with stavudine, didanosine and zidovudine. There have been reports of mitochondrial dysfunction in HIV negative infants exposed in utero and/or postnatally to nucleoside analogues; these have predominantly concerned treatment with regimens containing zidovudine. The main adverse reactions reported are haematological disorders (anaemia, neutropenia) and metabolic disorders (hyperlactatemia, hyperlipasemia). These events have often been transitory. Late onset neurological disorders have been reported rarely (hypertonia, convulsion, abnormal behaviour). Whether such neurological disorders are transient or permanent is currently unknown. These findings should be considered for any child exposed in utero to nucleos(t)ide analogues, who present with severe clinical findings of unknown etiology, particularly neurologic findings. These findings do not affect current national recommendations to use antiretroviral therapy in pregnant women to prevent vertical transmission of HIV.

Immune Reactivation Syndrome

In HIV infected patients with severe immune deficiency at the time of institution of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples include cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and Pneumocystis jirovecii pneumonia. Any inflammatory symptoms should be evaluated and treatment instituted when necessary.

Autoimmune disorders (such as Graves’ disease) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment.

Patients with HIV-1 harbouring mutations

Descovy should be avoided in antiretroviral-experienced patients with HIV-1 harbouring the K65R mutation (see section 5.1).

Triple nucleoside therapy

There have been reports of a high rate of virological failure and of emergence of resistance at an early stage when tenofovir disoproxil was combined with lamivudine and abacavir as well as with lamivudine and didanosine as a once daily regimen. Therefore, the same problems may be seen if Descovy is administered with a third nucleoside analogue.
Opportunistic infections

Patients receiving Descovy or any other antiretroviral therapy may continue to develop opportunistic infections and other complications of HIV infection, and, therefore, should remain under close clinical observation by physicians experienced in the treatment of patients with HIV associated diseases.

Osteonecrosis

Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV disease and/or long-term exposure to CART. Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.

Nephrotoxicity

A potential risk of nephrotoxicity resulting from chronic exposure to low levels of tenofovir due to dosing with tenofovir alafenamide cannot be excluded (see section 5.3).

Co-administration of other medicinal products

The co-administration of Descovy is not recommended with certain anticonvulsants (e.g., carbamazepine, oxcarbazepine, phenobarbital and phenytoin), antimycobacterials (e.g., rifampicin, rifabutin, rifapentine), boceprevir, St. John’s wort and HIV protease inhibitors (PIs) other than atazanavir, lopinavir and darunavir (see section 4.5).

Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil.

4.5 Interaction with other medicinal products and other forms of interaction

Interaction studies have only been performed in adults.

Descovy should not be administered concomitantly with medicinal products containing tenofovir alafenamide, tenofovir disoproxil, emtricitabine, lamivudine or adefovir dipivoxil.

Emtricitabine

*In vitro* and clinical pharmacokinetic drug-drug interaction studies have shown that the potential for CYP-mediated interactions involving emtricitabine with other medicinal products is low. Co-administration of emtricitabine with medicinal products that are eliminated by active tubular secretion may increase concentrations of emtricitabine, and/or the co-administered medicinal product. Medicinal products that decrease renal function may increase concentrations of emtricitabine.

Tenofovir alafenamide

Tenofovir alafenamide is transported by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). Medicinal products that strongly affect P-gp and BCRP activity may lead to changes in tenofovir alafenamide absorption. Medicinal products that induce P-gp activity (e.g., rifampicin, rifabutin, carbamazepine, phenobarbital) are expected to decrease the absorption of tenofovir alafenamide, resulting in decreased plasma concentration of tenofovir alafenamide, which may lead to loss of therapeutic effect of Descovy and development of resistance. Co-administration of Descovy with other medicinal products that inhibit P-gp and BCRP activity (e.g., cobicistat, ritonavir, ciclosporin) is expected to increase the absorption and plasma concentration of tenofovir alafenamide. Based on data from an *in vitro* study, co-administration of tenofovir alafenamide and xanthine oxidase inhibitors (e.g., febuxostat) is not expected to increase systemic exposure to tenofovir *in vivo*. 
Tenofovir alafenamide is not an inhibitor of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2D6 in vitro. It is not an inhibitor or inducer of CYP3A in vivo. Tenofovir alafenamide is a substrate of OATP1B1 and OATP1B3 in vitro. The distribution of tenofovir alafenamide in the body may be affected by the activity of OATP1B1 and OATP1B3.

Other interactions

Tenofovir alafenamide is not an inhibitor of human uridine diphosphate glucuronosyltransferase (UGT) 1A1 in vitro. It is not known whether tenofovir alafenamide is an inhibitor of other UGT enzymes. Emtricitabine did not inhibit the glucuronidation reaction of a non-specific UGT substrate in vitro.

Interactions between the components of Descovy and potential co-administered medicinal products are listed in Table 2 (increase is indicated as “↑”, decrease as “↓”, no change as “↔”). The interactions described are based on studies conducted with Descovy, or the components of Descovy as individual agents and/or in combination, or are potential drug-drug interactions that may occur with Descovy.

Table 2: Interactions between the individual components of Descovy and other medicinal products

<table>
<thead>
<tr>
<th>Medicinal product by therapeutic areas¹</th>
<th>Effects on medicinal product levels. Mean percent change in AUC, C&lt;sub&gt;max&lt;/sub&gt;, C&lt;sub&gt;min&lt;/sub&gt;²</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ANTI-INFECTIVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antifungals</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>Interaction not studied with either of the components of Descovy.</td>
<td>The recommended dose of Descovy is 200/10 mg once daily.</td>
</tr>
<tr>
<td>Itraconazole</td>
<td>Co-administration of ketoconazole or itraconazole, which are potent P-gp inhibitors, is expected to increase plasma concentrations of tenofovir alafenamide.</td>
<td></td>
</tr>
<tr>
<td>Fluconazole</td>
<td>Interaction not studied with either of the components of Descovy.</td>
<td>Dose Descovy according to the concomitant antiretroviral (see section 4.2).</td>
</tr>
<tr>
<td>Isavuconazole</td>
<td>Co-administration of fluconazole or isavuconazole may increase plasma concentrations of tenofovir alafenamide.</td>
<td></td>
</tr>
<tr>
<td><strong>Antimycobacterials</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifabutin</td>
<td>Interaction not studied with either of the components of Descovy.</td>
<td>Co-administration of Descovy and rifabutin rifampicin, or rifapentine is not recommended.</td>
</tr>
<tr>
<td>Rifampicin</td>
<td>Co-administration of rifampicin, rifabutin, and rifapentine, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance.</td>
<td></td>
</tr>
<tr>
<td>Rifapentine</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Anti-hepatitis C virus medicinal products</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boceprevir</td>
<td>Interaction not studied with either of the components of Descovy.</td>
<td>Co-administration with boceprevir has the potential to adversely affect the intracellular activation and clinical antiviral efficacy of tenofovir alafenamide, therefore co-administration of Descovy and boceprevir is not recommended.</td>
</tr>
<tr>
<td>Medicinal product by therapeutic areas</td>
<td>Effects on medicinal product levels. Mean percent change in AUC, $C_{\text{max}}$, $C_{\text{min}}$</td>
<td>Recommendation concerning co-administration with Descovy</td>
</tr>
<tr>
<td>--------------------------------------</td>
<td>-------------------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
</tbody>
</table>
| Ledipasvir (90 mg once daily)/ sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily) | Ledipasvir:  
AUC: ↑ 79%  
$C_{\text{max}}$: ↑ 65%  
$C_{\text{min}}$: ↑ 93%  
Sofosbuvir:  
AUC: ↑ 47%  
$C_{\text{max}}$: ↑ 29%  
Sofosbuvir metabolite GS-331007:  
AUC: ↑ 48%  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↑ 66%  
Emtricitabine:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  
Tenofovir alafenamide:  
AUC: ↔  
$C_{\text{max}}$: ↔ | No dose adjustment of ledipasvir or sofosbuvir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |
| Ledipasvir (90 mg once daily)/ sofosbuvir (400 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (25 mg once daily) | Ledipasvir:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  
Sofosbuvir:  
AUC: ↔  
$C_{\text{max}}$: ↔  
Sofosbuvir metabolite GS-331007:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  
Emtricitabine:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  
Tenofovir alafenamide:  
AUC: ↑ 32%  
$C_{\text{max}}$: ↔ | No dose adjustment of ledipasvir or sofosbuvir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |
<table>
<thead>
<tr>
<th>Medicinal product by therapeutic areas</th>
<th>Effects on medicinal product levels. Mean percent change in AUC, $C_{\text{max}}, C_{\text{min}}$</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
</table>
| Sofosbuvir (400 mg once daily)/ velpatasvir (100 mg once daily), emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily) | Sofosbuvir:  
AUC: ↑ 37%  
$C_{\text{max}}$: ↔  
Sofosbuvir metabolite GS-331007:  
AUC: ↑ 48%  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↑ 58%  
Velpatasvir:  
AUC: ↑ 50%  
$C_{\text{max}}$: ↑ 30%  
$C_{\text{min}}$: ↑ 60%  
Emtricitabine:  
AUC: ↔  
$C_{\text{max}}$: ↔  
$C_{\text{min}}$: ↔  
Tenofovir alafenamide:  
AUC: ↔  
$C_{\text{max}}$: ↓ 20% | No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |
| Sofosbuvir/velpatasvir/ voxilaprevir (400 mg/100 mg/100 mg+100 mg once daily)/ emtricitabine (200 mg once daily)/ tenofovir alafenamide (10 mg once daily) | Sofosbuvir:  
AUC: ↔  
$C_{\text{max}}$: ↑ 27%  
Sofosbuvir metabolite GS-331007:  
AUC: ↑ 43%  
$C_{\text{max}}$: ↔  
Velpatasvir:  
AUC: ↔  
$C_{\text{min}}$: ↑ 46%  
$C_{\text{max}}$: ↔  
Voxilaprevir:  
AUC: ↑ 171%  
$C_{\text{min}}$: ↑ 350%  
$C_{\text{max}}$: ↑ 92%  
Emtricitabine:  
AUC: ↔  
$C_{\text{min}}$: ↔  
$C_{\text{max}}$: ↔  
Tenofovir alafenamide:  
AUC: ↔  
$C_{\text{max}}$: ↓ 21% |
### Medicinal product by therapeutic areas

<table>
<thead>
<tr>
<th>Sofosbuvir/velpatasvir/voxilaprevir (400 mg/100 mg/100 mg once daily) / emtricitabine (200 mg once daily) / tenofovir alafenamide (25 mg once daily)</th>
<th>Sofosbuvir:</th>
<th>Mean percent change in AUC, C&lt;sub&gt;max&lt;/sub&gt;, C&lt;sub&gt;min&lt;/sub&gt;</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AUC: ↔</td>
<td></td>
<td>No dose adjustment of sofosbuvir, velpatasvir or voxilaprevir is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).</td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sofosbuvir metabolite GS-331007:</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Velpatasvir:</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Voxilaprevir:</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Emtricitabine:</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tenofovir alafenamide:</td>
<td>AUC: ↑ 52%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↑ 32%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### ANTIRETROVIRALS

**HIV protease inhibitors**

<table>
<thead>
<tr>
<th>Atazanavir/cobicistat (300 mg/150 mg once daily), tenofovir alafenamide (10 mg)</th>
<th>Tenofovir alafenamide:</th>
<th>Mean percent change in AUC, C&lt;sub&gt;max&lt;/sub&gt;, C&lt;sub&gt;min&lt;/sub&gt;</th>
<th>The recommended dose of Descovy is 200/10 mg once daily.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AUC: ↑ 75%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↑ 80%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atazanavir:</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Atazanavir/ritonavir (300/100 mg once daily), tenofovir alafenamide (10 mg)</th>
<th>Tenofovir alafenamide:</th>
<th>Mean percent change in AUC, C&lt;sub&gt;max&lt;/sub&gt;, C&lt;sub&gt;min&lt;/sub&gt;</th>
<th>The recommended dose of Descovy is 200/10 mg once daily.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AUC: ↑ 91%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↑ 77%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Atazanavir:</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Darunavir/cobicistat (800/150 mg once daily), tenofovir alafenamide (25 mg once daily)</th>
<th>Tenofovir alafenamide:</th>
<th>Mean percent change in AUC, C&lt;sub&gt;max&lt;/sub&gt;, C&lt;sub&gt;min&lt;/sub&gt;</th>
<th>The recommended dose of Descovy is 200/10 mg once daily.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AUC: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Darunavir:</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;max&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>C&lt;sub&gt;min&lt;/sub&gt;: ↔</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicinal product by therapeutic areas¹</td>
<td>Effects on medicinal product levels. Mean percent change in AUC, ( C_{\text{max}}, C_{\text{min}} )²</td>
<td>Recommendation concerning co-administration with Descovy</td>
<td></td>
</tr>
<tr>
<td>----------------------------------------</td>
<td>-------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>
| Darunavir/ritonavir (800/100 mg once daily), tenofovir alafenamide (10 mg once daily) | Tenofovir alafenamide:  
AUC: ↔  
\( C_{\text{max}} \): ↔  
Tenofovir:  
AUC: ↑ 105%  
\( C_{\text{max}} \): ↑ 142%  
Darunavir:  
AUC: ↔  
\( C_{\text{max}} \): ↔  
\( C_{\text{min}} \): ↔ | The recommended dose of Descovy is 200/10 mg once daily. |
| Lopinavir/ritonavir (800/200 mg once daily), tenofovir alafenamide (10 mg once daily) | Tenofovir alafenamide:  
AUC: ↑ 47%  
\( C_{\text{max}} \): ↑ 119%  
Lopinavir:  
AUC: ↔  
\( C_{\text{max}} \): ↔  
\( C_{\text{min}} \): ↔ | The recommended dose of Descovy is 200/10 mg once daily. |
| Tipranavir/ritonavir | Interaction not studied with either of the components of Descovy.  
Tipranavir/ritonavir results in P-gp induction. Tenofovir alafenamide exposure is expected to decrease when tipranavir/ritonavir is used in combination with Descovy. | Co-administration with Descovy is not recommended. |
| Other protease inhibitors | Effect is unknown. | There are no data available to make dosing recommendations for co-administration with other protease inhibitors. |

**Other HIV antiretrovirals**

| Dolutegravir (50 mg once daily), tenofovir alafenamide (10 mg once daily)³ | Tenofovir alafenamide:  
AUC: ↔  
\( C_{\text{max}} \): ↔  
Dolutegravir:  
AUC: ↔  
\( C_{\text{max}} \): ↔  
\( C_{\text{min}} \): ↔ | The recommended dose of Descovy is 200/25 mg once daily. |
| Rilpivirine (25 mg once daily), tenofovir alafenamide (25 mg once daily) | Tenofovir alafenamide:  
AUC: ↔  
\( C_{\text{max}} \): ↔  
Rilpivirine:  
AUC: ↔  
\( C_{\text{max}} \): ↔  
\( C_{\text{min}} \): ↔ | The recommended dose of Descovy is 200/25 mg once daily. |
| Efavirenz (600 mg once daily), tenofovir alafenamide (40 mg once daily)⁴ | Tenofovir alafenamide:  
AUC: ↓ 14%  
\( C_{\text{max}} \): ↓ 22% | The recommended dose of Descovy is 200/25 mg once daily. |
<table>
<thead>
<tr>
<th>Medicinal product by therapeutic areas¹</th>
<th>Effects on medicinal product levels. Mean percent change in AUC, $\text{C}<em>{\text{max}}, \text{C}</em>{\text{min}}$²</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maraviroc</td>
<td>Interaction not studied with either of the components of Descovy. Tenofovir alafenamide exposure is not expected to be affected by maraviroc, nevirapine or raltegravir, nor is it expected to affect the metabolic and excretion pathways relevant to maraviroc, nevirapine or raltegravir.</td>
<td>The recommended dose of Descovy is 200/25 mg once daily.</td>
</tr>
<tr>
<td>Nevirapine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raltegravir</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**ANTICONVULSANTS**

| Oxcarbazepine | Interaction not studied with either of the components of Descovy. Co-administration of oxcarbazepine, phenobarbital, or phenytoin, all of which are P-gp inducers, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. | Co-administration of Descovy and oxcarbazepine, phenobarbital or phenytoin is not recommended. |
| Phenobarbital |                                                    |                                                        |
| Phenytoin    |                                                    |                                                        |

Carbamazepine (titrated from 100 mg to 300 mg twice a day), emtricitabine/tenofovir alafenamide (200 mg/25 mg once daily)³⁵⁶

| Tenofovir alafenamide: | Co-administration of carbamazepine, a P-gp inducer, decreases tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. | Co-administration of Descovy and carbamazepine is not recommended. |
| AUC: ↓ 55% | |
| $\text{C}_{\text{max}}$: ↓ 57% | |

**ANTIDEPRESSANTS**

| Sertraline (50 mg once daily), tenofovir alafenamide (10 mg once daily)³ | Tenofovir alafenamide: AUC: ↔ $\text{C}_{\text{max}}$: ↔ | No dose adjustment of sertraline is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2). |
| Sertraline: | AUC: ↑ 9% $\text{C}_{\text{max}}$: ↑ 14% | |

**HERBAL PRODUCTS**

| St. John’s wort (Hypericum perforatum) | Interaction not studied with either of the components of Descovy. Co-administration of St. John’s wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. | Co-administration of Descovy with St. John’s wort is not recommended. |

**IMMUNOSUPPRESSANTS**

<p>| Ciclosporin | Interaction not studied with either of the components of Descovy. Co-administration of ciclosporin, a potent P-gp inhibitor, is expected to increase plasma concentrations of tenofovir alafenamide. | The recommended dose of Descovy is 200/10 mg once daily. |</p>
<table>
<thead>
<tr>
<th>Medicinal product by therapeutic areas¹</th>
<th>Effects on medicinal product levels. Mean percent change in AUC, (C_{\text{max}}, C_{\text{min}})²</th>
<th>Recommendation concerning co-administration with Descovy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ORAL CONTRACEPTIVES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norgestimate</td>
<td>Noregestromin:</td>
<td>No dose adjustment of norgestimate/ethinylestradiol is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).</td>
</tr>
<tr>
<td>(0.180/0.215/0.250 mg once daily),</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td>ethinylestradiol (0.025 mg once daily),</td>
<td>(C_{\text{max}}): ↔</td>
<td></td>
</tr>
<tr>
<td>emtricitabine/tenofovir alafenamide</td>
<td>(C_{\text{min}}): ↔</td>
<td></td>
</tr>
<tr>
<td>(200/25 mg once daily)⁵</td>
<td>(C_{\text{max}}): ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Norgestrel:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(C_{\text{max}}): ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(C_{\text{min}}): ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ethinylestradiol:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(C_{\text{max}}): ↔</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(C_{\text{min}}): ↔</td>
<td></td>
</tr>
<tr>
<td><strong>SEDATIVES/HYPNOTICS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Orally administered midazolam</td>
<td>Midazolam:</td>
<td>No dose adjustment of midazolam is required. Dose Descovy according to the concomitant antiretroviral (see section 4.2).</td>
</tr>
<tr>
<td>(2.5 mg single dose),</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td>tenofovir alafenamide (25 mg once</td>
<td>(C_{\text{max}}): ↔</td>
<td></td>
</tr>
<tr>
<td>daily)</td>
<td>(C_{\text{min}}): ↔</td>
<td></td>
</tr>
<tr>
<td>Intravenously administered midazolam</td>
<td>Midazolam:</td>
<td></td>
</tr>
<tr>
<td>(1 mg single dose),</td>
<td>AUC: ↔</td>
<td></td>
</tr>
<tr>
<td>tenofovir alafenamide (25 mg once</td>
<td>(C_{\text{max}}): ↔</td>
<td></td>
</tr>
<tr>
<td>daily)</td>
<td>(C_{\text{min}}): ↔</td>
<td></td>
</tr>
</tbody>
</table>

¹ When doses are provided, they are the doses used in clinical drug-drug interaction studies.
² When data are available from drug-drug interaction studies.
³ Study conducted with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination tablet.
⁴ Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet.
⁵ Study conducted with Descovy.
⁶ Emtricitabine/tenofovir alafenamide was taken with food in this study.
⁷ Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposures expected in HCV-infected patients.

4.6 Fertility, pregnancy and lactation

Pregnancy

There are no adequate and well-controlled studies of Descovy or its components in pregnant women. There are no or limited data (less than 300 pregnancy outcomes) from the use of tenofovir alafenamide in pregnant women. However, a large amount of data on pregnant women (more than 1,000 exposed outcomes) indicate no malformative nor foetal/neonatal toxicity associated with emtricitabine.

Animal studies do not indicate direct or indirect harmful effects of emtricitabine with respect to fertility parameters, pregnancy, foetal development, parturition or postnatal development. Studies of tenofovir alafenamide in animals have shown no evidence of harmful effects on fertility parameters, pregnancy, or foetal development (see section 5.3).

Descovy should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.

Breast-feeding

It is not known whether tenofovir alafenamide is excreted in human milk. Emtricitabine is excreted in human milk. In animal studies it has been shown that tenofovir is excreted in milk.

There is insufficient information on the effects of emtricitabine and tenofovir in newborns/infants. Therefore, Descovy should not be used during breast-feeding.
In order to avoid transmission of HIV to the infant it is recommended that HIV infected women do not breast-feed their infants under any circumstances.

Fertility

There are no data on fertility from the use of Descovy in humans. In animal studies there were no effects of emtricitabine and tenofovir alafenamide on mating or fertility parameters (see section 5.3).

4.7 Effects on ability to drive and use machines

Patients should be informed that dizziness has been reported during treatment with Descovy.

4.8 Undesirable effects

Summary of the safety profile

Assessment of adverse reactions is based on safety data from across all Phase 2 and 3 studies in which 3,112 HIV-1 infected patients received medicinal products containing emtricitabine and tenofovir alafenamide. In clinical studies of 866 treatment-naïve adult patients receiving emtricitabine and tenofovir alafenamide with elvitegravir and cobicistat as the fixed-dose combination tablet elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide (as fumarate) 10 mg (E/C/F/TAF) through 144 weeks, the most frequently reported adverse reactions were diarrhoea (7%), nausea (11%), and headache (6%).

Tabulated summary of adverse reactions

The adverse reactions in Table 3 are listed by system organ class and frequency. Frequencies are defined as follows: very common (≥ 1/10), common (≥ 1/100 to < 1/10) and uncommon (≥ 1/1,000 to < 1/100).

Table 3: Tabulated list of adverse reactions

<table>
<thead>
<tr>
<th>Frequency</th>
<th>Adverse reaction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
</tr>
<tr>
<td>Uncommon:</td>
<td>anaemia*</td>
</tr>
<tr>
<td>Psychiatry disorders</td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>abnormal dreams</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>headache, dizziness</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td></td>
</tr>
<tr>
<td>Very common:</td>
<td>nausea</td>
</tr>
<tr>
<td>Common:</td>
<td>diarrhoea, vomiting, abdominal pain, flatulence</td>
</tr>
<tr>
<td>Uncommon:</td>
<td>dyspepsia</td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>rash</td>
</tr>
<tr>
<td>Uncommon:</td>
<td>angioedema(^{2,3}), pruritus</td>
</tr>
<tr>
<td>Musculoskeletal and connective tissue disorders</td>
<td></td>
</tr>
<tr>
<td>Uncommon:</td>
<td>arthralgia</td>
</tr>
<tr>
<td>General disorders and administration site conditions</td>
<td></td>
</tr>
<tr>
<td>Common:</td>
<td>fatigue</td>
</tr>
</tbody>
</table>

1 With the exception of angioedema and anaemia (see footnotes 2 and 3), all adverse reactions were identified from clinical studies of F/TAF containing products. The frequencies were derived from Phase 3 E/C/F/TAF clinical studies in 866 treatment-naïve adult patients through 144 weeks of treatment (GS-US-292-0104 and GS-US-292-0111).

2 This adverse reaction was not observed in the clinical studies of F/TAF containing products but identified from clinical studies or post-marketing experience for emtricitabine when used with other antiretrovirals.

3 This adverse reaction was identified through post-marketing surveillance for emtricitabine but was not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies of emtricitabine. The frequency category of uncommon was estimated from a statistical calculation based on the total number of patients exposed to emtricitabine in these clinical studies (n = 1,563).
Description of selected adverse reactions

Immune Reactivation Syndrome
In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves’ disease) have also been reported; however, the reported time to onset is more variable, and these events can occur many months after initiation of treatment (see section 4.4).

Osteonecrosis
Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to CART. The frequency of this is unknown (see section 4.4).

Changes in lipid laboratory tests
In studies in treatment-naïve patients, increases from baseline were observed in both the tenofovir alafenamide fumarate and tenofovir disoproxil fumarate containing treatment groups for the fasting lipid parameters total cholesterol, direct low-density lipoprotein (LDL)- and high-density lipoprotein (HDL)-cholesterol, and triglycerides at Week 144. The median increase from baseline for those parameters was greater in the E/C/F/TAF group compared with the elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil (as fumarate) 245 mg (E/C/F/TDF) group at Week 144 (p < 0.001 for the difference between treatment groups for fasting total cholesterol, direct LDL- and HDL-cholesterol, and triglycerides). The median (Q1, Q3) change from baseline in total cholesterol to HDL-cholesterol ratio at Week 144 was 0.2 (-0.3, 0.7) in the E/C/F/TAF group and 0.1 (-0.4, 0.6) in the E/C/F/TDF group (p = 0.006 for the difference between treatment groups).

In a study of virologically suppressed patients switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent (Study GS-US-311-1089), increases from baseline were observed in the fasting lipid parameters total cholesterol, direct LDL cholesterol and triglycerides in the Descovy arm compared with little change in the emtricitabine/tenofovir disoproxil fumarate arm (p ≤ 0.009 for the difference between groups in changes from baseline). There was little change from baseline in median fasting values for HDL cholesterol and glucose, or in the fasting total cholesterol to HDL cholesterol ratio in either treatment arm at Week 96. None of the changes was considered clinically relevant.

In a study of virologically suppressed adult patients switching from abacavir/lamivudine to Descovy while maintaining the third antiretroviral agent (Study GS-US-311-1717), there were minimal changes in lipid parameters.

Metabolic parameters
Weight and levels of blood lipids and glucose may increase during antiretroviral therapy (see section 4.4).

Paediatric population
The safety of emtricitabine and tenofovir alafenamide was evaluated through 48 weeks in an open-label clinical study (GS-US-292-0106) in which HIV-1 infected, treatment-naïve paediatric patients aged 12 to < 18 years received emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet. The safety profile of emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat in 50 adolescent patients was similar to that in adults (see section 5.1).

Other special populations

Patients with renal impairment
The safety of emtricitabine and tenofovir alafenamide was evaluated through 144 weeks in an open-label clinical study (GS-US-292-0112) in which 248 HIV-1 infected patients who were either treatment-naïve (n = 6) or virologically suppressed (n = 242) with mild to moderate renal impairment
Patients co-infected with HIV and HBV

The safety of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF) was evaluated in 72 HIV/HBV co-infected patients receiving treatment for HIV in an open-label clinical study (GS-US-292-1249), through Week 48, in which patients were switched from another antiretroviral regimen (which included tenofovir disoproxil fumarate [TDF] in 69 of 72 patients) to E/C/F/TAF. Based on these limited data, the safety profile of emtricitabine and tenofovir alafenamide in combination with elvitegravir and cobicistat as a fixed-dose combination tablet, in patients with HIV/HBV co-infection, was similar to that in patients with HIV-1 monoinfection (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

If overdose occurs the patient must be monitored for evidence of toxicity (see section 4.8). Treatment of overdose with Descovy consists of general supportive measures including monitoring of vital signs as well as observation of the clinical status of the patient.

Emtricitabine can be removed by haemodialysis, which removes approximately 30% of the emtricitabine dose over a 3 hour dialysis period starting within 1.5 hours of emtricitabine dosing. Tenofovir is efficiently removed by haemodialysis with an extraction coefficient of approximately 54%. It is not known whether emtricitabine or tenofovir can be removed by peritoneal dialysis.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antiviral for systemic use; antivirals for treatment of HIV infections, combinations. ATC code: J05AR17.

Mechanism of action

Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) and nucleoside analogue of 2'-deoxycytidine. Emtricitabine is phosphorylated by cellular enzymes to form emtricitabine triphosphate. Emtricitabine triphosphate inhibits HIV replication through incorporation into viral deoxyribonucleic acid (DNA) by the HIV reverse transcriptase (RT), which results in DNA chain-termination. Emtricitabine has activity against HIV-1, HIV-2, and HBV.

Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) and phosphonamidate prodrug of tenofovir (2'-deoxyadenosine monophosphate analogue). Tenofovir alafenamide is permeable into cells and due to increased plasma stability and intracellular activation through hydrolysis by cathepsin A, tenofovir alafenamide is more efficient than tenofovir disoproxil fumarate in concentrating tenofovir in peripheral blood mononuclear cells (PBMCs) or HIV target cells including lymphocytes and macrophages. Intracellular tenofovir is subsequently phosphorylated to the pharmacologically active metabolite tenofovir diphosphate. Tenofovir diphosphate inhibits
HIV replication through incorporation into viral DNA by the HIV RT, which results in DNA chain-termination.

Tenofovir has activity against HIV-1, HIV-2, and HBV.

**Antiviral activity in vitro**

Emtricitabine and tenofovir alafenamide demonstrated synergistic antiviral activity in cell culture. No antagonism was observed with emtricitabine or tenofovir alafenamide when combined with other antiretroviral agents.

The antiviral activity of emtricitabine against laboratory and clinical isolates of HIV-1 was assessed in lymphoblastoid cell lines, the MAGI CCR5 cell line, and PBMCs. The 50% effective concentration (EC$_{50}$) values for emtricitabine were in the range of 0.0013 to 0.64 μM. Emtricitabine displayed antiviral activity in cell culture against HIV-1 clades A, B, C, D, E, F, and G (EC$_{50}$ values ranged from 0.007 to 0.075 μM) and showed strain specific activity against HIV-2 (EC$_{50}$ values ranged from 0.007 to 1.5 μM).

The antiviral activity of tenofovir alafenamide against laboratory and clinical isolates of HIV-1 subtype B was assessed in lymphoblastoid cell lines, PBMCs, primary monocyte/macrophage cells and CD4$^+$-T lymphocytes. The EC$_{50}$ values for tenofovir alafenamide were in the range of 2.0 to 14.7 nM. Tenofovir alafenamide displayed antiviral activity in cell culture against all HIV-1 groups (M, N, and O), including subtypes A, B, C, D, E, F, and G (EC$_{50}$ values ranged from 0.10 to 12.0 nM) and showed strain specific activity against HIV-2 (EC$_{50}$ values ranged from 0.91 to 2.63 nM).

**Resistance**

*In vitro*

Reduced susceptibility to emtricitabine is associated with M184V/I mutations in HIV-1 RT.

HIV-1 isolates with reduced susceptibility to tenofovir alafenamide express a K65R mutation in HIV-1 RT; in addition, a K70E mutation in HIV-1 RT has been transiently observed.

*In treatment-naïve patients*

In a pooled analysis of antiretroviral-naïve patients receiving emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet in Phase 3 studies GS-US-292-0104 and GS-US-292-0111, genotyping was performed on plasma HIV-1 isolates from all patients with HIV-1 RNA ≥ 400 copies/mL at confirmed virological failure, at Week 144, or at the time of early study drug discontinuation. Through Week 144, the development of one or more primary emtricitabine, tenofovir alafenamide, or elvitegravir resistance-associated mutations was observed in HIV-1 isolates from 12 of 22 patients with evaluable genotypic data from paired baseline and E/C/F/TAF treatment-failure isolates (12 of 866 patients [1.4%]) compared with 12 of 20 treatment-failure isolates from patients with evaluable genotypic data in the E/C/F/TDF group (12 of 867 patients [1.4%]). In the E/C/F/TAF group, the mutations that emerged were M184V/I (n = 11) and K65R/N (n = 2) in RT and T66T/A/I/V (n = 2), E92Q (n = 4), Q148Q/R (n = 1), and N155H (n = 2) in integrase. Of the HIV-1 isolates from 12 patients with resistance development in the E/C/F/TDF group, the mutations that emerged were M184V/I (n = 9), K65R/N (n = 4), and L210W (n = 1) in RT and E92Q/V (n = 4) and Q148R (n = 2), and N155H/S (n = 3) in integrase. Most HIV-1 isolates from patients in both treatment groups who developed resistance mutations to elvitegravir in integrase also developed resistance mutations to emtricitabine in RT.

*In patients co-infected with HIV and HBV*

In a clinical study of HIV virologically suppressed patients co-infected with chronic hepatitis B, who received emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), for 48 weeks (GS-US-292-1249, n = 72), 2 patients qualified for resistance analysis. In these 2 patients, no amino acid substitutions associated with resistance to any of the components of E/C/F/TAF were identified in HIV-1 or HBV.
Emtricitabine-resistant viruses with the M184V/I substitution were cross-resistant to lamivudine, but retained sensitivity to didanosine, stavudine, tenofovir, and zidovudine.

The K65R and K70E mutations result in reduced susceptibility to abacavir, didanosine, lamivudine, emtricitabine, and tenofovir, but retain sensitivity to zidovudine.

Multinucleoside-resistant HIV-1 with a T69S double insertion mutation or with a Q151M mutation complex including K65R showed reduced susceptibility to tenofovir alafenamide.

Clinical data

There are no efficacy and safety studies conducted in treatment-naïve patients with Descovy.

Clinical efficacy of Descovy was established from studies conducted with emtricitabine and tenofovir alafenamide when given with elvitegravir and cobicistat as the fixed-dose combination tablet E/C/F/TAF.

**HIV-1 infected, treatment-naïve patients**

In studies GS-US-292-0104 and GS-US-292-0111, patients were randomised in a 1:1 ratio to receive either emtricitabine 200 mg and tenofovir alafenamide 10 mg (n = 866) once daily or emtricitabine 200 mg + tenofovir disoproxil (as fumarate) 245 mg (n = 867) once daily, both given with elvitegravir 150 mg + cobicistat 150 mg as a fixed-dose combination tablet. The mean age was 36 years (range: 18-76), 85% were male, 57% were White, 25% were Black, and 10% were Asian. Nineteen percent of patients were identified as Hispanic/Latino. The mean baseline plasma HIV-1 RNA was 4.5 log_{10} copies/mL (range: 1.3-7.0) and 23% had baseline viral loads > 100,000 copies/mL. The mean baseline CD4+ cell count was 427 cells/mm³ (range: 0-1,360) and 13% had a CD4+ cell count < 200 cells/mm³.

E/C/F/TAF demonstrated statistical superiority in achieving HIV-1 RNA < 50 copies/mL when compared to E/C/F/TDF at Week 144. The difference in percentage was 4.2% (95% CI: 0.6% to 7.8%). Pooled treatment outcomes at 48 and 144 weeks are shown in Table 4.

**Table 4: Pooled virological outcomes of Studies GS-US-292-0104 and GS-US-292-0111 at Weeks 48 and 144**

<table>
<thead>
<tr>
<th></th>
<th>Week 48</th>
<th>Week 144</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>E/C/F/TAF (n = 866)</td>
<td>E/C/F/TDF (n = 867)</td>
</tr>
<tr>
<td>HIV-1 RNA &lt; 50 copies/mL</td>
<td>92%</td>
<td>90%</td>
</tr>
<tr>
<td>Treatment difference</td>
<td>2.0% (95% CI: -0.7% to 4.7%)</td>
<td>4.2% (95% CI: 0.6% to 7.8%)</td>
</tr>
<tr>
<td>HIV-1 RNA ≥ 50 copies/mL</td>
<td>4%</td>
<td>4%</td>
</tr>
<tr>
<td>No virologic data at Week 48 or 144 window</td>
<td>4%</td>
<td>6%</td>
</tr>
<tr>
<td>Discontinued study drug due to AE or death</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>Discontinued study drug due to other reasons and last available HIV-1 RNA &lt; 50 copies/mL</td>
<td>2%</td>
<td>4%</td>
</tr>
<tr>
<td>Missing data during window but on study drug</td>
<td>1%</td>
<td>&lt; 1%</td>
</tr>
<tr>
<td>Proportion (%) of patients with HIV-1 RNA &lt; 50 copies/mL by subgroup</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Week 48

<table>
<thead>
<tr>
<th></th>
<th>E/C/F/TAF (n = 866)</th>
<th>E/C/F/TDF (n = 867)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 50 years</td>
<td>716/777 (92%)</td>
<td>680/753 (90%)</td>
</tr>
<tr>
<td>≥ 50 years</td>
<td>84/89 (94%)</td>
<td>104/114 (91%)</td>
</tr>
<tr>
<td><strong>Sex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>674/733 (92%)</td>
<td>673/740 (91%)</td>
</tr>
<tr>
<td>Female</td>
<td>126/133 (95%)</td>
<td>111/127 (87%)</td>
</tr>
<tr>
<td><strong>Race</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>197/223 (88%)</td>
<td>177/213 (83%)</td>
</tr>
<tr>
<td>Non-black</td>
<td>603/643 (94%)</td>
<td>607/654 (93%)</td>
</tr>
<tr>
<td><strong>Baseline viral load</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 100,000 copies/mL</td>
<td>629/670 (94%)</td>
<td>610/672 (91%)</td>
</tr>
<tr>
<td>&gt; 100,000 copies/mL</td>
<td>171/196 (87%)</td>
<td>174/195 (89%)</td>
</tr>
<tr>
<td><strong>Baseline CD4+ cell count</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 200 cells/mm³</td>
<td>96/112 (86%)</td>
<td>104/117 (89%)</td>
</tr>
<tr>
<td>≥ 200 cells/mm³</td>
<td>703/753 (93%)</td>
<td>680/750 (91%)</td>
</tr>
<tr>
<td><strong>HIV-1 RNA &lt; 20 copies/mL</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment difference</td>
<td>84.4% (95% CI: -3.0% to 3.8%)</td>
<td>81.1% (95% CI: -3.0% to 3.8%)</td>
</tr>
</tbody>
</table>

E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide
E/C/F/TDF = elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate

a Week 48 window was between Day 294 and 377 (inclusive); Week 144 window was between Day 966 and 1049 (inclusive).
b In both studies, patients were stratified by baseline HIV-1 RNA (≤ 100,000 copies/mL, > 100,000 copies/mL to ≤ 400,000 copies/mL, or > 400,000 copies/mL), by CD4+ cell count (< 50 cells/μL, 50-199 cells/μL, or ≥ 200 cells/μL), and by region (US or ex-US).
c Included patients who had ≥ 50 copies/mL in the Week 48 or 144 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
d Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
e Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.

The mean increase from baseline in CD4+ cell count was 230 cells/mm³ in patients receiving E/C/F/TAF and 211 cells/mm³ in patients receiving E/C/F/TDF (p = 0.024) at Week 48, and 326 cells/mm³ in E/C/F/TAF-treated patients and 305 cells/mm³ in E/C/F/TDF-treated patients (p = 0.06) at Week 144.

Clinical efficacy of Descovy in treatment-naïve patients was also established from a study conducted with emtricitabine and tenofovir alafenamide (10 mg) when given with darunavir (800 mg) and cobicistat as a fixed-dose combination tablet (D/C/F/TAF). In Study GS-US-299-0102, patients were randomised in a 2:1 ratio to receive either fixed-dose combination D/C/F/TAF once daily (n = 103) or darunavir and cobicistat and emtricitabine/tenofovir disoproxil fumarate once daily (n = 50). The proportions of patients with plasma HIV-1 RNA < 50 copies/mL and < 20 copies/mL are shown in Table 5.
Table 5: Virological outcomes of Study GS-US-299-0102 at Week 24 and 48a

<table>
<thead>
<tr>
<th></th>
<th>Week 24</th>
<th></th>
<th>Week 48</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>D/C/F/TAF (n = 103)</td>
<td>Darunavir, cobicistat and emtricitabine/tenofovir disoproxil fumarate (n = 50)</td>
<td>D/C/F/TAF (n = 103)</td>
<td>Darunavir, cobicistat and emtricitabine/tenofovir disoproxil fumarate (n = 50)</td>
</tr>
<tr>
<td>HIV-1 RNA &lt; 50 copies/mL</td>
<td>75%</td>
<td>74%</td>
<td>77%</td>
<td>84%</td>
</tr>
<tr>
<td>HIV-1 RNA ≥ 50 copies/mL</td>
<td>20%</td>
<td>24%</td>
<td>16%</td>
<td>12%</td>
</tr>
<tr>
<td>No virologic data at Week 48 window</td>
<td>5%</td>
<td>2%</td>
<td>8%</td>
<td>4%</td>
</tr>
<tr>
<td>Discontinued study drug due to AE or deathc</td>
<td>1%</td>
<td>0%</td>
<td>1%</td>
<td>2%</td>
</tr>
<tr>
<td>Discontinued study drug due to other reasons and last available HIV-1 RNA &lt; 50 copies/mLd</td>
<td>4%</td>
<td>2%</td>
<td>7%</td>
<td>2%</td>
</tr>
<tr>
<td>Missing data during window but on study drug</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>HIV-1 RNA &lt; 20 copies/mL</td>
<td>55%</td>
<td>62%</td>
<td>63%</td>
<td>76%</td>
</tr>
<tr>
<td>Treatment difference</td>
<td>-3.5% (95% CI: -19.8% to 12.7%)</td>
<td>-10.7% (95% CI: -26.3% to 4.8%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D/C/F/TAF = darunavir/cobicistat/emtricitabine/tenofovir alafenamide

a Week 48 window was between Day 294 and 377 (inclusive).
b Included patients who had ≥ 50 copies/mL in the Week 48 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.
c Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.
d Includes patients who discontinued for reasons other than an AE, death or lack or loss of efficacy; e.g., withdrew consent, loss to follow-up, etc.

**HIV-1 infected virologically suppressed patients**

In Study GS-US-311-1089, the efficacy and safety of switching from emtricitabine/tenofovir disoproxil fumarate to Descovy while maintaining the third antiretroviral agent were evaluated in a randomised, double-blind study of virologically suppressed HIV-1 infected adults (n = 663). Patients must have been stably suppressed (HIV-1 RNA < 50 copies/mL) on their baseline regimen for at least 6 months and had HIV-1 with no resistance mutations to emtricitabine or tenofovir alafenamide prior to study entry. Patients were randomised in a 1:1 ratio to either switch to Descovy (n = 333), or stay on their baseline emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330). Patients were stratified by the class of the third agent in their prior treatment regimen. At baseline, 46% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with a boosted PI and 54% of patients were receiving emtricitabine/tenofovir disoproxil fumarate in combination with an unboosted third agent.

Treatment outcomes of Study GS-US-311-1089 through 48 and 96 weeks are presented in Table 6.
Table 6: Virological outcomes of Study GS-US-311-1089 at Weeks 48<sup>a</sup> and 96<sup>b</sup>

<table>
<thead>
<tr>
<th></th>
<th>Week 48</th>
<th>Week 96</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Descovy containing regimen (n = 333)</td>
<td>Descovy containing regimen (n = 333)</td>
</tr>
<tr>
<td></td>
<td>Emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330)</td>
<td>Emtricitabine/tenofovir disoproxil fumarate containing regimen (n = 330)</td>
</tr>
<tr>
<td>HIV-1 RNA &lt; 50 copies/mL</td>
<td>94%</td>
<td>93%</td>
</tr>
<tr>
<td>Treatment difference</td>
<td>1.3% (95% CI: -2.5% to 5.1%)</td>
<td>-0.5% (95% CI: -5.3% to 4.4%)</td>
</tr>
<tr>
<td>HIV-1 RNA ≥ 50 copies/mL&lt;sup&gt;c&lt;/sup&gt;</td>
<td>&lt; 1%</td>
<td>2%</td>
</tr>
<tr>
<td>No virologic data at Week 48 or 96 window</td>
<td>5%</td>
<td>9%</td>
</tr>
<tr>
<td>Discontinued study drug due to AE or death&lt;sup&gt;d&lt;/sup&gt;</td>
<td>2%</td>
<td>2%</td>
</tr>
<tr>
<td>Discontinued study drug due to other reasons and last available HIV-1 RNA &lt; 50 copies/mL&lt;sup&gt;e&lt;/sup&gt;</td>
<td>3%</td>
<td>5%</td>
</tr>
<tr>
<td>Missing data during window but on study drug</td>
<td>&lt; 1%</td>
<td>0</td>
</tr>
<tr>
<td>Proportion (%) of patients with HIV-1 RNA &lt; 50 copies/mL by prior treatment regimen</td>
<td>142/155 (92%)</td>
<td>133/155 (86%)</td>
</tr>
<tr>
<td>Boosted PIs</td>
<td>140/151 (93%)</td>
<td>162/178 (91%)</td>
</tr>
<tr>
<td>Other third agents</td>
<td>167/179 (93%)</td>
<td>162/179 (91%)</td>
</tr>
<tr>
<td>PI = protease inhibitor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>a Week 48 window was between Day 294 and 377 (inclusive).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>b Week 96 window was between Day 630 and 713 (inclusive).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>c Included patients who had ≥ 50 copies/mL in the Week 48 or Week 96 window; patients who discontinued early due to lack or loss of efficacy; patients who discontinued for reasons other than an adverse event (AE), death or lack or loss of efficacy and at the time of discontinuation had a viral value of ≥ 50 copies/mL.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>d Includes patients who discontinued due to AE or death at any time point from Day 1 through the time window if this resulted in no virologic data on treatment during the specified window.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>e Includes patients who discontinued for reasons other than an AE, death or lack of efficacy; e.g., withdrew consent, loss to follow-up, etc.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

In Study GS-US-311-1717, patients who were virologically suppressed (HIV-1 RNA < 50 copies/mL) on their abacavir/lamivudine containing regimen for at least 6 months were randomised in a 1:1 ratio to either switch to Descovy (N=280) while maintaining their third agent at baseline or stay on their baseline abacavir/lamivudine-containing regimen (N=276).

Patients were stratified by the class of the third agent in their prior treatment regimen. At baseline, 30% of patients were receiving abacavir/lamivudine in combination with a boosted protease inhibitor and 70% of patients were receiving abacavir/lamivudine in combination with an unboosted third agent. Virologic success rates at Week 48 were: Descovy Containing Regimen: 89.7% (227 of 253 subjects); Abacavir/lamivudine Containing Regimen: 92.7% (230 of 248 subjects). In Week 48, switching to a
Descovy-containing regimen was non-inferior to staying on a baseline abacavir/lamivudine-containing regimen in maintaining HIV-1 RNA < 50 copies/mL.

**HIV-1 infected patients with mild to moderate renal impairment**

In Study GS-US-292-0112, the efficacy and safety of emtricitabine and tenofovir alafenamide were evaluated in an open-label clinical study in which 242 HIV-1 infected patients with mild to moderate renal impairment (eGFR<sub>C</sub>; 30-69 mL/min) were switched to emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet. Patients were virologically suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months before switching.

The mean age was 58 years (range: 24-82), with 63 patients (26%) who were ≥ 65 years of age. Seventy-nine percent were male, 63% were White, 18% were Black, and 14% were Asian. Thirteen percent of patients were identified as Hispanic/Latino. At baseline, median eGFR was 56 mL/min, and 33% of patients had an eGFR from 30 to 49 mL/min. The mean baseline CD4+ cell count was 664 cells/mm<sup>3</sup> (range: 126-1,813).

At Week 144, 83.1% (197/237 patients) maintained HIV-1 RNA < 50 copies/mL after switching to emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet.

**Patients co-infected with HIV and HBV**

In open-label Study GS-US-292-1249, the efficacy and safety of emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet (E/C/F/TAF), were evaluated in adult patients co-infected with HIV-1 and chronic hepatitis B. Sixty-nine of the 72 patients were on prior TDF-containing antiretroviral therapy. At the start of treatment with E/C/F/TAF, the 72 patients had been HIV-suppressed (HIV-1 RNA < 50 copies/mL) for at least 6 months with or without suppression of HBV DNA and had compensated liver function. The mean age was 50 years (range 28-67), 92% of patients were male, 69% were White, 18% were Black, and 10% were Asian. The mean baseline CD4+ cell count was 636 cells/mm<sup>3</sup> (range 263-1498).

Eighty-six percent of patients (62/72) were HBV suppressed (HBV DNA < 29 IU/mL) and 42% (30/72) were HBeAg positive at baseline.

Of the patients who were HBeAg positive at baseline, 1/30 (3.3%) achieved seroconversion to anti-HBe at Week 48. Of the patients who were HBsAg positive at baseline, 3/70 (4.3%) achieved seroconversion to anti-HBs Week 48.

At Week 48, 92% of patients (66/72) maintained HIV-1 RNA < 50 copies/mL after switching to emtricitabine and tenofovir alafenamide, given with elvitegravir and cobicistat as a fixed-dose combination tablet. The mean change from baseline in CD4+ cell count at Week 48 was -2 cells/mm<sup>3</sup>. Ninety-two percent (66/72 patients) had HBV DNA < 29 IU/mL using missing = failure analysis at Week 48. Of the 62 patients who were HBV suppressed at baseline, 59 remained suppressed and 3 had missing data. Of the 10 patients who were not HBV suppressed at baseline (HBV DNA ≥ 29 IU/mL), 7 became suppressed, 2 remained detectable, and 1 had missing data.

There are limited clinical data on the use of E/C/F/TAF in HIV/HBV co-infected patients who are treatment-naïve.

**Changes in measures of bone mineral density**

In studies in treatment-naïve patients, emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet was associated with smaller reductions in bone mineral density (BMD) compared to E/C/F/TDF through 144 weeks of treatment as measured by dual energy X ray absorptiometry (DXA) analysis of hip (mean change: −0.8% vs −3.4%, p < 0.001) and lumbar spine (mean change: −0.9% vs −3.0%, p < 0.001). In a separate study, emtricitabine and tenofovir alafenamide given with darunavir and cobicistat as a fixed-dose combination tablet was also associated with smaller reductions in BMD (as measured by hip and lumbar spine DXA analysis) through 48 weeks of treatment compared to darunavir, cobicistat, emtricitabine and tenofovir disoproxil fumarate.
In a study in virologically suppressed adult patients, improvements in BMD were noted through 96 weeks after switching to Descovy from a TDF containing regimen compared to minimal changes with maintaining the TDF containing regimen as measured by DXA analysis of hip (mean change from baseline of 1.9% vs -0.3%, p < 0.001) and lumbar spine (mean change from baseline of 2.2% vs -0.2%, p < 0.001).

In a study in virologically suppressed adult patients, BMD did not change significantly through 48 weeks after switching to Descovy from an abacavir/lamivudine containing regimen compared to maintaining the abacavir/lamivudine containing regimen as measured by DXA analysis of hip (mean change from baseline of 0.3% vs 0.2%, p = 0.55) and lumbar spine (mean change from baseline of 0.1% vs < 0.1%, p = 0.78).

Changes in measures of renal function
In studies in treatment-naïve patients, emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat as a fixed-dose combination tablet through 144 weeks was associated with a lower impact on renal safety parameters (as measured after 144 weeks treatment by eGFRCG and urine protein to creatinine ratio and after 96 weeks treatment by urine albumin to creatinine ratio) compared to E/C/F/TDF. Through 144 weeks of treatment, no subject discontinued E/C/F/TAF due to a treatment-emergent renal adverse event compared with 12 subjects who discontinued E/C/F/TDF (p < 0.001).

In a separate study in treatment-naïve patients, emtricitabine and tenofovir alafenamide given with darunavir and cobicistat as a fixed-dose combination tablet was associated with a lower impact on renal safety parameters through 48 weeks of treatment compared to darunavir and cobicistat given with emtricitabine/tenofovir disoprophil fumarate (see also section 4.4).

In a study in virologically suppressed adult patients measures of tubular proteinuria were similar in patients switching to a regimen containing Descovy compared to patients who stayed on an abacavir/lamivudine containing regimen at baseline. At Week 48, the median percentage change in urine retinol binding protein to creatinine ratio was 4% in the Descovy group and 16% in those remaining on an abacavir/lamivudine containing regimen; and in urine beta-2 microglobulin to creatinine ratio it was 4% vs. 5%.

Paediatric population
In Study GS-US-292-0106, the efficacy, safety, and pharmacokinetics of emtricitabine and tenofovir alafenamide were evaluated in an open-label study in which 50 HIV-1 infected, treatment-naïve adolescents received emtricitabine and tenofovir alafenamide (10 mg) given with elvitegravir and cobicistat as a fixed-dose combination tablet. Patients had a mean age of 15 years (range: 12-17), and 56% were female, 12% were Asian, and 88% were Black. At baseline, median plasma HIV-1 RNA was \(4.7 \log_{10} \text{copies/mL}\), median CD4+ cell count was 456 cells/mm\(^3\) (range: 95-1,110), and median CD4+% was 23% (range: 7-45%). Overall, 22% had baseline plasma HIV-1 RNA > 100,000 copies/mL. At 48 weeks, 92% (46/50) achieved HIV-1 RNA < 50 copies/mL, similar to response rates in studies of treatment-naïve HIV-1 infected adults. The mean increase from baseline in CD4+ cell count at Week 48 was 224 cells/mm\(^3\). No emergent resistance to E/C/F/TAF was detected through Week 48.

The European Medicines Agency has deferred the obligation to submit the results of studies with Descovy in one or more subsets of the paediatric population in the treatment of HIV-1 infection (see section 4.2 for information on paediatric use).
5.2 Pharmacokinetic properties

Absorption

Emtricitabine is rapidly and extensively absorbed following oral administration with peak plasma concentrations occurring at 1 to 2 hours post-dose. Following multiple dose oral administration of emtricitabine to 20 HIV-1 infected subjects, the (mean ± SD) steady state plasma emtricitabine peak concentrations (C\text{max}) were 1.8 ± 0.7 μg/mL and the area-under the plasma concentration-time curve over a 24-hour dosing interval (AUC) was 10.0 ± 3.1 μg•h/mL. The mean steady state plasma trough concentration at 24 hours post-dose was equal to or greater than the mean in vitro IC90 value for anti-HIV-1 activity.

Emtricitabine systemic exposure was unaffected when emtricitabine was administered with food. Following administration of food in healthy subjects, peak plasma concentrations were observed approximately 1 hour post-dose for tenofovir alafenamide administered as F/TAF (25 mg) or E/C/F/TAF (10 mg). The mean C\text{max} and AUC\text{last}, (mean ± SD) under fed conditions following a single 25 mg dose of tenofovir alafenamide administered in Descovy were 0.21 ± 0.13 μg/mL and 0.25 ± 0.11 μg•h/mL, respectively. The mean C\text{max} and AUC\text{last} following a single 10 mg dose of tenofovir alafenamide administered in E/C/F/TAF were 0.21 ± 0.10 μg/mL and 0.25 ± 0.08 μg•h/mL, respectively.

Relative to fasting conditions, the administration of tenofovir alafenamide with a high fat meal (~800 kcal, 50% fat) resulted in a decrease in tenofovir alafenamide C\text{max} (15-37%) and an increase in AUC\text{last} (17-77%).

Distribution

In vitro binding of emtricitabine to human plasma proteins was < 4% and independent of concentration over the range of 0.02-200 μg/mL. At peak plasma concentration, the mean plasma to blood drug concentration ratio was ~1.0 and the mean semen to plasma drug concentration ratio was ~4.0.

In vitro binding of tenofovir to human plasma proteins is < 0.7% and is independent of concentration over the range of 0.01-25 μg/mL. Ex vivo binding of tenofovir alafenamide to human plasma proteins in samples collected during clinical studies was approximately 80%.

Biotransformation

In vitro studies indicate that emtricitabine is not an inhibitor of human CYP enzymes. Following administration of [14C]-emtricitabine, complete recovery of the emtricitabine dose was achieved in urine (~86%) and faeces (~14%). Thirteen percent of the dose was recovered in the urine as three putative metabolites. The biotransformation of emtricitabine includes oxidation of the thiol moiety to form the 3’-sulfoxide diastereomers (~9% of dose) and conjugation with glucuronic acid to form 2’-O-glucuronide (~4% of dose). No other metabolites were identifiable.

Metabolism is a major elimination pathway for tenofovir alafenamide in humans, accounting for > 80% of an oral dose. In vitro studies have shown that tenofovir alafenamide is metabolised to tenofovir (major metabolite) by cathepsin A in PBMCs (including lymphocytes and other HIV target cells) and macrophages; and by carboxylesterase-1 in hepatocytes. In vivo, tenofovir alafenamide is hydrolysed within cells to form tenofovir (major metabolite), which is phosphorylated to the active metabolite tenofovir diphosphate. In human clinical studies, a 10 mg oral dose of tenofovir alafenamide (given with emtricitabine and elvitegravir and cobicistat) resulted in tenofovir diphosphate concentrations > 4-fold higher in PBMCs and > 90% lower concentrations of tenofovir in plasma as compared to a 245 mg oral dose of tenofovir disoproxil (as fumarate) (given with emtricitabine and elvitegravir and cobicistat).
In vitro, tenofovir alafenamide is not metabolised by CYP1A2, CYP2C8, CYP2C9, CYP2C19, or CYP2D6. Tenofovir alafenamide is minimally metabolised by CYP3A4. Upon co-administration with the moderate CYP3A inducer probe efavirenz, tenofovir alafenamide exposure was not significantly affected. Following administration of tenofovir alafenamide, plasma $^{14}$C-radioactivity showed a time-dependent profile with tenofovir alafenamide as the most abundant species in the initial few hours and uric acid in the remaining period.

**Elimination**

Emtricitabine is primarily excreted by the kidneys with complete recovery of the dose achieved in urine (approximately 86%) and faeces (approximately 14%). Thirty percent of the emtricitabine dose was recovered in urine as three metabolites. The systemic clearance of emtricitabine averaged 307 mL/min. Following oral administration, the elimination half-life of emtricitabine is approximately 10 hours.

Renal excretion of intact tenofovir alafenamide is a minor pathway with < 1% of the dose eliminated in urine. Tenofovir alafenamide is mainly eliminated following metabolism to tenofovir. Tenofovir alafenamide and tenofovir have a median plasma half-life of 0.51 and 32.37 hours, respectively. Tenofovir is renally eliminated by both glomerular filtration and active tubular secretion.

**Pharmacokinetics in special populations**

**Age, gender, and ethnicity**

No clinically relevant pharmacokinetic differences due to age, gender or ethnicity have been identified for emtricitabine, or tenofovir alafenamide.

**Paediatric population**

Exposures of emtricitabine and tenofovir alafenamide (given with elvitegravir and cobicistat) achieved in 24 paediatric patients aged 12 to < 18 years who received emtricitabine and tenofovir alafenamide given with elvitegravir and cobicistat in Study GS-US-292-0106 were similar to exposures achieved in treatment-naïve adults (Table 7).

**Table 7: Pharmacokinetics of emtricitabine and tenofovir alafenamide in antiretroviral-naïve adolescents and adults**

<table>
<thead>
<tr>
<th></th>
<th>Adolescents</th>
<th>Adults</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>FTC$^a$</td>
<td>TAF$^b$</td>
</tr>
<tr>
<td>AUC$_{\text{tau}}$ (ng·h/mL)</td>
<td>14,424.4 (23.9)</td>
<td>242.8 (57.8)</td>
</tr>
<tr>
<td>C$_{\text{max}}$ (ng/mL)</td>
<td>2,265.0 (22.5)</td>
<td>121.7 (46.2)</td>
</tr>
<tr>
<td>C$_{\text{tau}}$ (ng/mL)</td>
<td>102.4 (38.9)$^b$</td>
<td>N/A</td>
</tr>
</tbody>
</table>

E/C/F/TAF = elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate

FTC = emtricitabine; TAF = tenofovir alafenamide fumarate; TFV = tenofovir

N/A = not applicable

Data are presented as mean (%CV).

a n = 24 adolescents (GS-US-292-0106); n = 19 adults (GS-US-292-0102)
b n = 23 adolescents (GS-US-292-0106, population PK analysis)
c n = 539 (TAF) or 841 (TFV) adults (GS-US-292-0111 and GS-US-292-0104, population PK analysis)

**Renal impairment**

No clinically relevant differences in tenofovir alafenamide, or tenofovir pharmacokinetics were observed between healthy subjects and patients with severe renal impairment (estimated CrCl > 15 but < 30 mL/min) in studies of tenofovir alafenamide. There are no pharmacokinetic data on tenofovir alafenamide in patients with estimated CrCl < 15 mL/min. Mean systemic emtricitabine exposure was higher in patients with severe renal impairment (CrCl < 30 mL/min) (33.7 μg·h/mL) than in subjects with normal renal function (11.8 μg·h/mL).
Hepatic impairment
The pharmacokinetics of emtricitabine have not been studied in subjects with hepatic impairment; however, emtricitabine is not significantly metabolised by liver enzymes, so the impact of liver impairment should be limited.

Clinically relevant changes in the pharmacokinetics of tenofovir alafenamide or its metabolite tenofovir were not observed in patients with mild or moderate hepatic impairment. In patients with severe hepatic impairment, total plasma concentrations of tenofovir alafenamide and tenofovir are lower than those seen in subjects with normal hepatic function. When corrected for protein binding, unbound (free) plasma concentrations of tenofovir alafenamide in severe hepatic impairment and normal hepatic function are similar.

Hepatitis B and/or hepatitis C virus co-infection
The pharmacokinetics of emtricitabine and tenofovir alafenamide have not been fully evaluated in patients co-infected with HBV and/or HCV.

5.3 Preclinical safety data
Non-clinical data on emtricitabine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Emtricitabine has demonstrated low carcinogenic potential in mice and rats.

Non-clinical studies of tenofovir alafenamide in rats and dogs revealed bone and kidney as the primary target organs of toxicity. Bone toxicity was observed as reduced BMD in rats and dogs at tenofovir exposures at least four times greater than those expected after administration of Descovy. A minimal infiltration of histiocytes was present in the eye in dogs at tenofovir alafenamide and tenofovir exposures of approximately 4 and 17 times greater, respectively, than those expected after administration of Descovy.

Tenofovir alafenamide was not mutagenic or clastogenic in conventional genotoxicity assays.

Because there is a lower tenofovir exposure in rats and mice after the administration of tenofovir alafenamide compared to tenofovir disoproxil fumarate, carcinogenicity studies and a rat peri-postnatal study were conducted only with tenofovir disoproxil fumarate. No special hazard for humans was revealed in conventional studies of carcinogenic potential and toxicity to reproduction and development. Reproductive toxicity studies in rats and rabbits showed no effects on mating, fertility, pregnancy or foetal parameters. However, tenofovir disoproxil fumarate reduced the viability index and weight of pups in a peri-postnatal toxicity study at maternally toxic doses.

6. Pharmaceutical particulars

6.1 List of excipients

Tablet core

Microcrystalline cellulose
Croscarmellose sodium
Magnesium stearate
Film-coating

Polyvinyl alcohol
Titanium dioxide
Macrogol 3350
Talc
Indigo carmine aluminium lake (E132)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

Store in the original package in order to protect from moisture. Keep the bottle tightly closed.

6.5 Nature and contents of container

High density polyethylene (HDPE) bottle with a polypropylene continuous-thread, child-resistant cap, lined with an induction activated aluminium foil liner containing 30 film-coated tablets. Each bottle contains silica gel desiccant and polyester coil.

The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1099/003
EU/1/16/1099/004

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 21 April 2016
10. DATE OF REVISION OF THE TEXT

{MM/YYYY}

Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu.
ANNEX II

A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE

Name and address of the manufacturer(s) responsible for batch release

Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland

B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

- Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation.

D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT

- Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.
ANNEX III

LABELLING AND PACKAGE LEAFLET
A. LABELLING
PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING

BOTTLE AND CARTON LABELLING

1. NAME OF THE MEDICINAL PRODUCT

Descovy 200 mg/10 mg film-coated tablets
emtricitabine/tenofovir alafenamide

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Each film-coated tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.

3. LIST OF EXCIPIENTS

4. PHARMACEUTICAL FORM AND CONTENTS

30 film-coated tablets

90 (3 bottles of 30) film-coated tablets

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

Oral use.

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN

Keep out of the sight and reach of children.

7. OTHER SPECIAL WARNING(S), IF NECESSARY

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Store in the original package in order to protect from moisture. Keep the bottle tightly closed.
| 10. | SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE |
| 11. | NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER |
| Gilead Sciences Ireland UC |
| Carrigtohill |
| County Cork, T45 DP77 |
| Ireland |
| 12. | MARKETING AUTHORISATION NUMBER(S) |
| EU/1/16/1099/001 30 film-coated tablets |
| EU/1/16/1099/002 90 (3 bottles of 30) film-coated tablets |
| 13. | BATCH NUMBER |
| Lot |
| 14. | GENERAL CLASSIFICATION FOR SUPPLY |
| 15. | INSTRUCTIONS ON USE |
| Descovy 200 mg/10 mg [Outer packaging only] |
| 17. | UNIQUE IDENTIFIER – 2D BARCODE |
| 2D barcode carrying the unique identifier included. |
| 18. | UNIQUE IDENTIFIER - HUMAN READABLE DATA |
| PC: {number} |
| SN: {number} |
| NN: {number} |
**PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING**

**BOTTLE AND CARTON LABELLING**

<table>
<thead>
<tr>
<th>1. NAME OF THE MEDICINAL PRODUCT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Descovy 200 mg/25 mg film-coated tablets emtricitabine/tenofovir alafenamide</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2. STATEMENT OF ACTIVE SUBSTANCE(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Each film-coated tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3. LIST OF EXCIPIENTS</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>4. PHARMACEUTICAL FORM AND CONTENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 film-coated tablets</td>
</tr>
<tr>
<td>90 (3 bottles of 30) film-coated tablets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5. METHOD AND ROUTE(S) OF ADMINISTRATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Read the package leaflet before use.</td>
</tr>
<tr>
<td>Oral use.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE SIGHT AND REACH OF CHILDREN</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keep out of the sight and reach of children.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7. OTHER SPECIAL WARNING(S), IF NECESSARY</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>8. EXPIRY DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXP</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>9. SPECIAL STORAGE CONDITIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Store in the original package in order to protect from moisture. Keep the bottle tightly closed.</td>
</tr>
</tbody>
</table>
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE

11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Gilead Sciences Ireland UC
Carrigtobin
County Cork, T45 DP77
Ireland

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/16/1099/003 30 film-coated tablets
EU/1/16/1099/004 90 (3 bottles of 30) film-coated tablets

13. BATCH NUMBER

Lot

14. GENERAL CLASSIFICATION FOR SUPPLY

15. INSTRUCTIONS ON USE

16. INFORMATION IN BRAILLE

Descovy 200 mg/25 mg [Outer packaging only]

17. UNIQUE IDENTIFIER – 2D BARCODE

2D barcode carrying the unique identifier included.

18. UNIQUE IDENTIFIER - HUMAN READABLE DATA

PC: {number}
SN: {number}
NN: {number}
B. PACKAGE LEAFLET
Package leaflet: Information for the user

Descovy 200 mg/10 mg film-coated tablets
emtricitabine/tenofovir alafenamide

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Descovy is and what it is used for
2. What you need to know before you take Descovy
3. How to take Descovy
4. Possible side effects
5. How to store Descovy
6. Contents of the pack and other information

1. What Descovy is and what it is used for

Descovy contains two active substances:

- **emtricitabine**, an antiretroviral medicine of a type known as a nucleoside reverse transcriptase inhibitor (NRTI)
- **tenofovir alafenamide**, an antiretroviral medicine of a type known as a nucleotide reverse transcriptase inhibitor (NtRTI)

Descovy blocks the action of the reverse transcriptase enzyme, which is essential for the virus to multiply. Descovy therefore reduces the amount of HIV in your body.

Descovy in combination with other medicines is for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.

2. What you need to know before you take Descovy

Do not take Descovy:
- **If you are allergic to emtricitabine, tenofovir alafenamide** or any of the other ingredients of this medicine (listed in section 6 of this leaflet).

Warnings and precautions

You must remain under the care of your doctor while taking Descovy.

You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your doctor the precautions needed to avoid infecting other
people. This medicine is not a cure for HIV infection. While taking Descovy you may still develop infections or other illnesses associated with HIV infection.

**Talk to your doctor before taking Descovy:**

- **If you have liver problems or have suffered liver disease, including hepatitis.** Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. If you have hepatitis B infection, your doctor will carefully consider the best treatment regimen for you.

  If you have hepatitis B liver problems may become worse after you stop taking Descovy. Do not stop taking Descovy without talking to your doctor: see section 3, *Do not stop taking Descovy.*

- Your doctor may not prescribe Descovy to you if the virus has a K65R mutation.

**While you are taking Descovy**

Once you start taking Descovy, look out for:

- Signs of inflammation or infection
- Joint pain, stiffness or bone problems

⇒ *If you notice any of these symptoms, tell your doctor immediately.* For more information see section 4, *Possible side effects.*

Although kidney problems have not been observed with Descovy, there is a possibility that you may experience kidney problems when taking Descovy over a long period of time.

**Children and adolescents**

*Do not give this medicine to children* aged 11 years or under, or weighing less than 35 kg. The use of Descovy in children aged 11 years or under has not yet been studied.

**Other medicines and Descovy**

**Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.** Descovy may interact with other medicines. As a result, the amounts of Descovy or other medicines in your blood may change. This may stop your medicines from working properly, or may make any side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.

**Medicines used in treating hepatitis B infection:**

You should not take Descovy with medicines containing:

- tenofovir alafenamide
- tenofovir disoproxil
- lamivudine
- adefovir dipivoxil

⇒ *Tell your doctor* if you are taking any of these medicines.

**Other types of medicine:**

Talk to your doctor if you are taking:

- **antibiotics,** used to treat bacterial infections including tuberculosis, containing:
  - rifabutin, rifampicin, and rifapentine
- antiviral medicines used to treat hepatitis C:
  - boceprevir
- antiviral medicines used to treat HIV:
  - emtricitabine and tipranavir
- anticonvulsants, used to treat epilepsy, such as:
  - carbamazepine, oxcarbazepine, phenobarbital and phenytoin
- herbal remedies used to treat depression and anxiety containing:
  - St. John’s wort (*Hypericum perforatum*)

Tell your doctor if you are taking these or any other medicines. Do not stop your treatment without contacting your doctor.

Pregnancy and breast-feeding

- If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
- Use effective contraception while taking Descovy.

Ask your doctor or pharmacist for advice before taking any medicine when pregnant.

If you have taken Descovy during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.

Do not breast-feed during treatment with Descovy. This is because one of the active substances in this medicine passes into breast milk. It is recommended that you do not breast-feed to avoid passing the virus to the baby through breast milk.

Driving and using machines

Descovy can cause dizziness. If you feel dizzy when taking Descovy, do not drive and do not use any tools or machines.

3. How to take Descovy

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is:

- **Adults**: one tablet each day, with or without food
- **Adolescents 12 years of age and older, who weigh at least 35 kg**: one tablet each day with or without food

Do not chew, crush or split the tablet.

Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.

If you take more Descovy than you should

If you take more than the recommended dose of Descovy you may be at higher risk of side effects of this medicine (see section 4, Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can show what you have taken.

If you forget to take Descovy

It is important not to miss a dose of Descovy.

If you do miss a dose:
- **If you notice within 18 hours** of the time you usually take Descovy, you must take the tablet as soon as possible. Then take the next dose as usual.
- **If you notice 18 hours or more** after the time you usually take Descovy, then do not take the missed dose. Wait and take the next dose at your usual time.

If you vomit less than 1 hour after taking Descovy, take another tablet.

Do not stop taking Descovy

Do not stop taking Descovy without talking to your doctor. Stopping Descovy can seriously affect how well future treatment works. If Descovy is stopped for any reason, speak to your doctor before you restart taking Descovy tablets.

When your supply of Descovy starts to run low, get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The disease may then become harder to treat.

If you have both HIV infection and hepatitis B, it is very important not to stop taking Descovy without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.

➤ Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Possible serious side effects: tell a doctor immediately

- **Any signs of inflammation or infection.** In some patients with advanced HIV infection (AIDS) and who have had opportunistic infections in the past (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after antiretroviral treatment is started. It is thought that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
- **Autoimmune disorders** (the immune system attacks healthy body tissue), may also occur after you start taking medicines for HIV infection. Autoimmune disorders may occur many months after the start of treatment. Look out for any symptoms of infection or other symptoms such as:
  - muscle weakness
  - weakness beginning in the hands and feet and moving up towards the trunk of the body
  - palpitations, tremor or hyperactivity

➤ If you notice the side effects described above, tell your doctor immediately.
**Very common side effects**  
*may affect more than 1 in 10 people*
- feeling sick (*nausea*)

**Common side effects**  
*may affect up to 1 in 10 people*
- abnormal dreams
- headache
- dizziness
- diarrhoea
- vomiting
- stomach pain
- wind (*flatulence*)
- rash
- tiredness (*fatigue*)

**Uncommon side effects**  
*may affect up to 1 in 100 people*
- low red blood cell count (*anaemia*)
- problems with digestion resulting in discomfort after meals (*dyspepsia*)
- swelling of the face, lips, tongue or throat (*angioedema*)
- itching (*pruritus*)
- joint pain (*arthritis*)

→ If any of the side effects get serious tell your doctor.

**Other effects that may be seen during HIV treatment**

The frequency of the following side effects is not known (frequency cannot be estimated from the available data).

- **Bone problems.** Some patients taking combination antiretroviral medicines such as Descovy may develop a bone disease called *osteonecrosis* (death of bone tissue caused by loss of blood supply to the bone). Taking this type of medicine for a long time, taking corticosteroids, drinking alcohol, having a very weak immune system, and being overweight, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are:
  - joint stiffness
  - joint aches and pains (especially of the hip, knee and shoulder)
  - difficulty with movement

→ If you notice any of these symptoms tell your doctor.

During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.

**Reporting of side effects**

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.

By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Descovy**

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after “EXP”. The expiry date refers to the last day of that month.

Store in the original package in order to protect from moisture. Keep the bottle tightly closed.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Descovy contains

The active substances are emtricitabine and tenofovir alafenamide. Each Descovy film-coated tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 10 mg of tenofovir alafenamide.

The other ingredients are

Tablet core: Microcrystalline cellulose, croscarmellose sodium, magnesium stearate.

Film-coating: Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, iron oxide black (E172).

What Descovy looks like and contents of the pack

Descovy film-coated tablets are grey, rectangular-shaped tablets, debossed on one side with “GSI” and the number “210” on the other side of the tablet.

Descovy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets). The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.

The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.

Marketing Authorisation Holder:
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Ireland

Manufacturer:
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtohill
County Cork
Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Contact Information</th>
</tr>
</thead>
</table>
| België/Belgique/Belgien | Gilead Sciences Belgium SPRL-BVBA  
Tél/Tel: + 32 (0) 24 01 35 50 |
| Bългария     | Gilead Sciences Ireland UC  
Tel.: + 353 (0) 1 686 1888 |
| Česká republika | Gilead Sciences s.r.o.  
Tel: + 420 910 871 986 |
| Danmark      | Gilead Sciences Sweden AB  
Tlf: + 46 (0) 8 5057 1849 |
| Deutschland  | Gilead Sciences GmbH  
Tel: + 49 (0) 89 899890-0 |
| Eestí        | Gilead Sciences Poland Sp. z o.o.  
Tel: +48 22 262 8702 |
| Ελλάδα       | Gilead Sciences Ελλάς Μ.ΕΠΕ.  
Τηλ: + 30 210 8930 100 |
| España       | Gilead Sciences, S.L.  
Tel: + 34 91 378 98 30 |
| France       | Gilead Sciences  
Tél: + 33 (0) 1 46 09 41 00 |
| Hrvatska     | Gilead Sciences Ireland UC  
Tel: + 353 (0) 1 686 1888 |
| Ireland      | Gilead Sciences Ireland UC  
Tel: + 353 (0) 214 825 999 |
| Ísland       | Gilead Sciences Sweden AB  
Sími: + 46 (0) 8 5057 1849 |
| Italia       | Gilead Sciences S.r.l.  
Tel: + 39 02 439201 |
| Lietuva      | Gilead Sciences Poland Sp. z o.o.  
Tel: +48 22 262 8702 |
| Luxemburg/Luxemburg | Gilead Sciences Belgium SPRL-BVBA  
Tél/Tel: + 32 (0) 24 01 35 50 |
| Magyarország | Gilead Sciences Ireland UC  
Tel: + 353 (0) 1 686 1888 |
| Malta        | Gilead Sciences Ireland UC  
Tel: + 353 (0) 1 686 1888 |
| Nederland    | Gilead Sciences Netherlands B.V.  
Tel: + 31 (0) 20 718 36 98 |
| Norge        | Gilead Sciences Sweden AB  
Tlf: + 46 (0) 8 5057 1849 |
| Österreich   | Gilead Sciences GesmbH  
Tel: + 43 1 260 830 |
| Polska       | Gilead Sciences Poland Sp. z o.o.  
Tel: +48 22 262 8702 |
| Portugal     | Gilead Sciences, Lda.  
Tel: + 351 21 7928790 |
| România      | Gilead Sciences Ireland UC  
Tel: + 353 (0) 1 686 1888 |
| Slovenija    | Gilead Sciences Ireland UC  
Tel: + 353 (0) 1 686 1888 |
| Slovenská republika | Gilead Sciences Slovakia s.r.o.  
Tel: + 421 232 121 210 |
| Suomi/Finnland | Gilead Sciences Sweden AB  
Puh/Tel: + 46 (0) 8 5057 1849 |
This leaflet was last revised in {}MM/YYYY} <{}month YYYY}.<{}month YYYY}.

Detailed information on this medicine is available on the European Medicines Agency web site:
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet
1. What Descovy is and what it is used for
2. What you need to know before you take Descovy
3. How to take Descovy
4. Possible side effects
5. How to store Descovy
6. Contents of the pack and other information

1. What Descovy is and what it is used for

Descovy contains two active substances:

- **emtricitabine**, an antiretroviral medicine of a type known as a nucleoside reverse transcriptase inhibitor (NRTI)
- **tenofovir alafenamide**, an antiretroviral medicine of a type known as a nucleotide reverse transcriptase inhibitor (NtRTI)

Descovy blocks the action of the reverse transcriptase enzyme, which is essential for the virus to multiply. Descovy therefore reduces the amount of HIV in your body.

Descovy in combination with other medicines is for the treatment of human immunodeficiency virus 1 (HIV-1) infection in adults and adolescents 12 years of age and older, who weigh at least 35 kg.

2. What you need to know before you take Descovy

Do not take Descovy:
- If you are allergic to emtricitabine, tenofovir alafenamide or any of the other ingredients of this medicine (listed in section 6 of this leaflet).

Warnings and precautions

You must remain under the care of your doctor while taking Descovy.

You can still pass on HIV when taking this medicine, although the risk is lowered by effective antiretroviral therapy. Discuss with your doctor the precautions needed to avoid infecting other
people. This medicine is not a cure for HIV infection. While taking Descovy you may still develop infections or other illnesses associated with HIV infection.

**Talk to your doctor before taking Descovy:**

- **If you have liver problems or have suffered liver disease, including hepatitis.** Patients with liver disease including chronic hepatitis B or C, who are treated with antiretrovirals, have a higher risk of severe and potentially fatal liver complications. If you have hepatitis B infection, your doctor will carefully consider the best treatment regimen for you.

  If you have hepatitis B liver problems may become worse after you stop taking Descovy. Do not stop taking Descovy without talking to your doctor: see section 3, *Do not stop taking Descovy.*

- Your doctor may not prescribe Descovy to you if the virus has a K65R mutation.

**While you are taking Descovy**

Once you start taking Descovy, look out for:

- Signs of inflammation or infection
- Joint pain, stiffness or bone problems

⇒ If you notice any of these symptoms, tell your doctor immediately. For more information see section 4, *Possible side effects.*

Although kidney problems have not been observed with Descovy, there is a possibility that you may experience kidney problems when taking Descovy over a long period of time.

**Children and adolescents**

**Do not give this medicine to children** aged 11 years or under, or weighing less than 35 kg. The use of Descovy in children aged 11 years or under has not yet been studied.

**Other medicines and Descovy**

**Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.** Descovy may interact with other medicines. As a result, the amounts of Descovy or other medicines in your blood may change. This may stop your medicines from working properly, or may make any side effects worse. In some cases, your doctor may need to adjust your dose or check your blood levels.

**Medicines used in treating hepatitis B infection:**

You should not take Descovy with medicines containing:

- tenofovir alafenamide
- tenofovir disoproxil
- lamivudine
- adefovir dipivoxil

⇒ *Tell your doctor* if you are taking any of these medicines.

**Other types of medicine:**

Talk to your doctor if you are taking:

- **antibiotics,** used to treat bacterial infections including tuberculosis, containing:
  - rifabutin, rifampicin, and rifapentine
• antiviral medicines used to treat hepatitis C:
  - boceprevir
• antiviral medicines used to treat HIV:
  - emtricitabine and tipranavir
• anticonvulsants, used to treat epilepsy, such as:
  - carbamazepine, oxcarbazepine, phenobarbital and phenytoin
• herbal remedies used to treat depression and anxiety containing:
  - St. John’s wort (Hypericum perforatum)

→ Tell your doctor if you are taking these or any other medicines. Do not stop your treatment without contacting your doctor.

Pregnancy and breast-feeding

• If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
• Use effective contraception while taking Descovy.

Ask your doctor or pharmacist for advice before taking any medicine when pregnant.

If you have taken Descovy during your pregnancy, your doctor may request regular blood tests and other diagnostic tests to monitor the development of your child. In children whose mothers took NRTIs during pregnancy, the benefit from the protection against HIV outweighed the risk of side effects.

Do not breast-feed during treatment with Descovy. This is because one of the active substances in this medicine passes into breast milk. It is recommended that you do not breast-feed to avoid passing the virus to the baby through breast milk.

Driving and using machines
Descovy can cause dizziness. If you feel dizzy when taking Descovy, do not drive and do not use any tools or machines.

3. How to take Descovy

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.

The recommended dose is:

Adults: one tablet each day, with or without food
Adolescents 12 years of age and older, who weigh at least 35 kg: one tablet each day with or without food

Do not chew, crush or split the tablet.

Always take the dose recommended by your doctor. This is to make sure that your medicine is fully effective, and to reduce the risk of developing resistance to the treatment. Do not change the dose unless your doctor tells you to.

If you take more Descovy than you should

If you take more than the recommended dose of Descovy you may be at higher risk of side effects of this medicine (see section 4, Possible side effects).
Contact your doctor or nearest emergency department immediately for advice. Keep the tablet bottle with you so that you can show what you have taken.

If you forget to take Descovy

It is important not to miss a dose of Descovy.

If you do miss a dose:
- If you notice within 18 hours of the time you usually take Descovy, you must take the tablet as soon as possible. Then take the next dose as usual.
- If you notice 18 hours or more after the time you usually take Descovy, then do not take the missed dose. Wait and take the next dose at your usual time.

If you vomit less than 1 hour after taking Descovy, take another tablet.

Do not stop taking Descovy

Do not stop taking Descovy without talking to your doctor. Stopping Descovy can seriously affect how well future treatment works. If Descovy is stopped for any reason, speak to your doctor before you restart taking Descovy tablets.

When your supply of Descovy starts to run low, get more from your doctor or pharmacist. This is very important because the amount of virus may start to increase if the medicine is stopped for even a short time. The disease may then become harder to treat.

If you have both HIV infection and hepatitis B, it is very important not to stop taking Descovy without talking to your doctor first. You may require blood tests for several months after stopping treatment. In some patients with advanced liver disease or cirrhosis, stopping treatment may lead to worsening of hepatitis, which may be life-threatening.

⇒ Tell your doctor immediately about new or unusual symptoms after you stop treatment, particularly symptoms you associate with hepatitis B infection.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Possible serious side effects: tell a doctor immediately

- Any signs of inflammation or infection. In some patients with advanced HIV infection (AIDS) and who have had opportunistic infections in the past (infections that occur in people with a weak immune system), signs and symptoms of inflammation from previous infections may occur soon after antiretroviral treatment is started. It is thought that these symptoms are due to an improvement in the body’s immune response, enabling the body to fight infections that may have been present with no obvious symptoms.
- Autoimmune disorders (the immune system attacks healthy body tissue), may also occur after you start taking medicines for HIV infection. Autoimmune disorders may occur many months after the start of treatment. Look out for any symptoms of infection or other symptoms such as:
  - muscle weakness
  - weakness beginning in the hands and feet and moving up towards the trunk of the body
  - palpitations, tremor or hyperactivity
⇒ If you notice the side effects described above, tell your doctor immediately.
Very common side effects
\((may \text{ affect more than 1 in } 10 \text{ people})\)
- feeling sick (nausea)

Common side effects
\((may \text{ affect up to 1 in } 10 \text{ people})\)
- abnormal dreams
- headache
- dizziness
- diarrhoea
- vomiting
- stomach pain
- wind (flatulence)
- rash
- tiredness (fatigue)

Uncommon side effects
\((may \text{ affect up to 1 in } 100 \text{ people})\)
- low red blood cell count (anaemia)
- problems with digestion resulting in discomfort after meals (dyspepsia)
- swelling of the face, lips, tongue or throat (angioedema)
- itching (pruritus)
- joint pain (arthritis)

➔ If any of the side effects get serious tell your doctor.

Other effects that may be seen during HIV treatment

The frequency of the following side effects is not known (frequency cannot be estimated from the available data).

- **Bone problems.** Some patients taking combination antiretroviral medicines such as Descovy may develop a bone disease called osteonecrosis (death of bone tissue caused by loss of blood supply to the bone). Taking this type of medicine for a long time, taking corticosteroids, drinking alcohol, having a very weak immune system, and being overweight, may be some of the many risk factors for developing this disease. Signs of osteonecrosis are:
  - joint stiffness
  - joint aches and pains (especially of the hip, knee and shoulder)
  - difficulty with movement

➔ If you notice any of these symptoms tell your doctor.

During HIV therapy there may be an increase in weight and in levels of blood lipids and glucose. This is partly linked to restored health and life style, and in the case of blood lipids sometimes to the HIV medicines themselves. Your doctor will test for these changes.

Reporting of side effects

If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V.

By reporting side effects you can help provide more information on the safety of this medicine.

5. **How to store Descovy**

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and bottle after “EXP”. The expiry date refers to the last day of that month.

Store in the original package in order to protect from moisture. Keep the bottle tightly closed.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Descovy contains

The active substances are emtricitabine and tenofovir alafenamide. Each Descovy film-coated tablet contains 200 mg of emtricitabine and tenofovir alafenamide fumarate equivalent to 25 mg of tenofovir alafenamide.

The other ingredients are

Tablet core:
Microcrystalline cellulose, croscarmellose sodium, magnesium stearate.

Film-coating:
Polyvinyl alcohol, titanium dioxide, macrogol 3350, talc, indigo carmine aluminium lake (E132).

What Descovy looks like and contents of the pack

Descovy film-coated tablets are blue, rectangular-shaped tablets, debossed on one side with “GSI” and the number “225” on the other side of the tablet.

Descovy comes in bottles of 30 tablets (with a silica gel desiccant that must be kept in the bottle to help protect your tablets). The silica gel desiccant is contained in a separate sachet or canister and should not be swallowed.

The following pack sizes are available: outer cartons containing 1 bottle of 30 film-coated tablets and outer cartons containing 90 (3 bottles of 30) film-coated tablets. Not all pack sizes may be marketed.

Marketing Authorisation Holder:
Gilead Sciences Ireland UC
Carrigtwohill
County Cork, T45 DP77
Ireland

Manufacturer:
Gilead Sciences Ireland UC
IDA Business & Technology Park
Carrigtowhill
County Cork
Ireland
For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

<table>
<thead>
<tr>
<th>Country</th>
<th>Contact Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Belgïë/Belgique/Belgien</td>
<td>Gilead Sciences Belgium SPRL-BVBA Tél/Tel: +32 (0) 24 01 35 50</td>
</tr>
<tr>
<td>България</td>
<td>Gilead Sciences Ireland UC Тел.: +353 (0) 1 686 1888</td>
</tr>
<tr>
<td>Česká republika</td>
<td>Gilead Sciences s.r.o. Tel: +420 910 871 986</td>
</tr>
<tr>
<td>Данmark</td>
<td>Gilead Sciences Sweden AB Tlf: +46 (0) 8 5057 1849</td>
</tr>
<tr>
<td>Deutschand</td>
<td>Gilead Sciences GmbH Tel: +49 (0) 89 899890-0</td>
</tr>
<tr>
<td>Eestï</td>
<td>Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702</td>
</tr>
<tr>
<td>Ελλάδα</td>
<td>Gilead Sciences Ελλάς Μ.ΕΒΕ. Τηλ: +30 210 8930 100</td>
</tr>
<tr>
<td>Espaňa</td>
<td>Gilead Sciences, S.L. Tel: +34 91 378 98 30</td>
</tr>
<tr>
<td>Франція</td>
<td>Gilead Sciences Tél: +33 (0) 1 46 09 41 00</td>
</tr>
<tr>
<td>Хрватска</td>
<td>Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888</td>
</tr>
<tr>
<td>Ирландія</td>
<td>Gilead Sciences Ireland UC. Tel: +353 (0) 214 825 999</td>
</tr>
<tr>
<td>Ісланд</td>
<td>Gilead Sciences Sweden AB Сими: +46 (0) 8 5057 1849</td>
</tr>
<tr>
<td>Італія</td>
<td>Gilead Sciences S.r.l. Tel: +39 02 439201</td>
</tr>
<tr>
<td>Litva</td>
<td>Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702</td>
</tr>
<tr>
<td>Люксембург</td>
<td>Gilead Sciences Belgium SPRL-BVBA Tél/Tel: +32 (0) 24 01 35 50</td>
</tr>
<tr>
<td>Magyarország</td>
<td>Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888</td>
</tr>
<tr>
<td>Malta</td>
<td>Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888</td>
</tr>
<tr>
<td>Нідерланди</td>
<td>Gilead Sciences Netherlands B.V. Tel: +31 (0) 20 718 36 98</td>
</tr>
<tr>
<td>Норвегія</td>
<td>Gilead Sciences Sweden AB Tlf: +46 (0) 8 5057 1849</td>
</tr>
<tr>
<td>Õstereich</td>
<td>Gilead Sciences GesmbH Tel: +43 1 260 830</td>
</tr>
<tr>
<td>Polska</td>
<td>Gilead Sciences Poland Sp. z o.o. Tel: +48 22 262 8702</td>
</tr>
<tr>
<td>Португалія</td>
<td>Gilead Sciences, Lda. Tel: +351 21 7928790</td>
</tr>
<tr>
<td>România</td>
<td>Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888</td>
</tr>
<tr>
<td>Словенія</td>
<td>Gilead Sciences Ireland UC Tel: +353 (0) 1 686 1888</td>
</tr>
<tr>
<td>Словенскá републіка</td>
<td>Gilead Sciences Slovakia s.r.o. Tel: +421 232 121 210</td>
</tr>
<tr>
<td>Suomi/Finland</td>
<td>Gilead Sciences Sweden AB Puh/Tel: +46 (0) 8 5057 1849</td>
</tr>
</tbody>
</table>
This leaflet was last revised in <MM/YYYY> <month YYYYY>.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.